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Abstract 
Persisting high-risk human papillomavirus (HPV) infection is a major cause of cervical 
cancer, which develops from cervical intraepithelial neoplasia (CIN). “High-risk” HPVs, in 
particular HPV16 and HPV18, are able to evade immunosurveillance in some patients, and 
create a suppressive local immune environment. Expression of viral protein E7 causes a 
dysregulated cell cycle, a result of E7 and Rb protein interaction, leading to epithelial 
hyperplasia of the infected area. A suppressive local immune environment has been 
observed in E7-expressing mouse skin with a thickened epithelial layer. Previously, animal 
studies on immune responses against persisting high-risk HPV infection have not separated 
the effects of expression of viral protein E7 from the effects of the accompanying skin 
hyperplasia. However, hyperproliferative epithelium can contribute to the change of immune 
responses by secreting a unique profile of cytokines and chemokines. In this project, mice 
expressing the HPV16 E7 protein as a transgene in keratinocytes, with (K14.E7xRbΔL/ΔL) or 
without (K14.E7) disrupted interaction of E7 with Rb in keratinocytes are utilised. The 
epithelial transcriptome, subsets of skin-infiltrating/ residing immune cells, and immune 
responses are analysed in these mice, and compared with non-transgenic mice. I have thus 
investigated separately the contribution of E7 protein expression, and of E7-Rb interaction-
associated skin hyperplasia, to the suppressive local immune environment.  
 
Suppressed peripheral immune responses were observed in the K14.E7 transgenic animals. 
These correlated with up-regulated regulatory cytokine secretion, infiltration of regulatory 
immune cells and ineffective antigen presentation, and comparison with K14.E7xRbΔL/ΔL 
mice allowed me to establish that these were a consequence of hyperproliferative 
epithelium, rather than of E7 expression. Further, keratinocytes of K14.E7xRbΔL/ΔL were able 
to present both exogenous E7 peptide, and endogenous (transgenic) E7 antigen, enabling 
antigen-specific T cell lysis in vitro, whereas keratinocytes of K14.E7 mice were only able to 
present exogenous E7 peptide effectively to T cells. To understand the changes induced by 
E7-Rb interaction and its associated epithelial hyperplasia, whole skin RNA sequencing was 
utilised. A unique profile of cytokine/ chemokine secretion that associated with epithelial 
hyperplasia alone was identified. In particular, chemokines CXCL9 and CXCL10 were highly 
upregulated in non-haematopoietic cells in the hyperproliferative epithelium and recruit 
CXCR3+ lymphocytes to the hyperplastic skin. Overexpression of CXCL9 and CXCL10 is 
not observed in K14.E7xRbΔL/ΔL skin, and CXCR3+ T cells are preferentially recruited by 
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CXCL9 and CXCL10 in supernatants of K14.E7 but not K14.E7xRbΔL/ΔL skin cultures in vitro. 
CXCR3 signalling promotes infiltration of a subset of effector T lymphocytes that enables 
rejection of donor lymphocyte deficient, E7-expressing skin grafts. This suggests that 
recruitment of CXCR3+ T cells can be an important factor in the rejection of precancerous 
skin epithelium providing they can overcome local immunosuppressive mechanisms driven 
by skin-resident lymphocytes. In comparison to the suppressive local immunity of K14.E7 
skin, skin immune responses were induced normally in the K14.E7xRbΔL/ΔL transgenic 
mouse. It was therefore expected that the K14.E7xRbΔL/ΔL skin, unlike K14.E7 skin, would 
be rejected when transplant onto syngeneic non-transgenic recipients. However, rejection 
was not observed, even when the skin was grafted onto transgenic recipients with E7-
specific cytotoxic T cells and E7 specific immunisation. Skin-derived CD11b+ DCs were 
present in reduced numbers in the skin draining lymph node of K14.E7xRbΔL/ΔL skin graft 
recipients, when compared with non-transgenic skin graft recipients. Thus, I hypothesise 
that this may contribute to impaired rejection of K14.E7xRbΔL/ΔL skin. Taken together, the 
hyperplastic epithelium contributes to CXCR3+ effector T cell recruitment. However, the 
CXCR3+ T cell population is insufficient to overcome the locally suppressed immune 
environment generated by E7-Rb interaction and its associated epithelial hyperplasia. 
Disruption of the interaction can only partially restore the immune responses, as the skin 
without E7-Rb interaction was not rejected when transplanted.  
 
In summary, this project provides evidence that highlights the differential role of HPV16E7 
expression and E7-Rb interaction-associated hyperplasia and gains insights to the local 
immune responses against persistent HPV infection.  
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1.1 Literature Review 
Human papillomavirus infection and cancer 
Human papillomavirus (HPV) is a double-stranded DNA virus without viral surface lipid 
envelope. There are over 180 types of HPV identified. HPV infections are restricted to 
keratinocytes of the skin and mucosal tissues (Frazer, 2004). Infection by low-risk HPV types 
results in benign genital warts and benign warts on other parts of the body, while high-risk 
HPV type16 and 18 are responsible for 70% of cervical cancer (Durst et al., 1983). Moreover, 
increased incidence of head and neck cancers caused by high-risk HPV infection has been 
observed and the incidence rate has sharply increased during the past two decades (Gillison 
et al., 2012; Gillison et al., 2014; WORLD HEALTH ORGANIZATION International Agency 
for Research on Cancer Multicenter Cervical Cancer Study, 2007) Although preventative 
vaccination has been implemented widely and made the diseases preventable, therapeutic 
strategies for existing infections are not as prominent. Understanding how the high-risk HPV 
infection impacts on an individual is then thus critical to develop potent therapies for 
persistent infections.  
 
The genome of HPV is about 8000 base pairs, encoding early viral proteins-E1, E2, 
E4, E5, E6, and E7, as well as late proteins-L1 and L2 (Figure 1), and is typically located 
extrachromosomally in an infected cell. The replication of the virus does not induce viraemia 
and cytolysis throughout the course of the infection cycle. This enables HPV to replicate in 
a silent manner and thus evade host immune surveillance (Kupper and Fuhlbrigge, 2004).  
 
Figure 1.1. HPV16 genome structure  
(graph remade form (Stanley et al., 2007)). 
The genome structure of the double stranded 
DNA virus HPV16 includes long control region 
(LCR) as enhancer and promoter region, early 
proteins (E1-E7) that sustain viral replication and 
late proteins (L1 and L2) for viral structure. 
 
The HPV viral infection cycle is highly 
dependent on keratinocyte differentiation, where it establishes its replication niche in the 
proliferative basal layer of the epithelium and expresses low levels of early viral proteins. As 
the keratinocytes differentiate, the amount of early protein expression increases. The late 
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proteins (L1 and L2) encoding capsid proteins are only expressed in terminally differentiated 
keratinocytes. In contrast to the late proteins, the early proteins are responsible for the viral 
replication throughout all disease stages. E1 acts as an ATPase and helicase for viral 
genome replication (Ustav et al., 1991). E2 protein is a sequence-specific DNA binding 
protein that initiates transcription of viral genes (Bouvard et al., 1994). E4 protein induces 
productive infection (Foguel et al., 1998) and E5 induces proliferation by stimulating the 
transforming activity of epidermal growth factor receptor (EGFR) (zur Hausen, 2001). E6 
facilitates ubiquitination of the p53 tumour suppressor protein and thus promotes its 
degradation (Huibregtse et al., 1993). E7 interacts with the retinoblastoma protein (Rb) and 
disrupts its interaction with E2F1. The unbound E2F1 then activates excessive transcription 
signals for cell proliferation and replication (Cobrinik et al., 1992; Nevins, 1992). The acute 
cellular defects of HPV infection, including dysregulated cell cycle progression, 
differentiation and DNA damage response, are dependent on the binding of E7 with Rb 
(Balsitis et al., 2003; Jacks et al., 1992; Slebos et al., 1994). Apart from Rb interaction-
dependent mechanisms, epithelial expression of the E7 protein in both Rb-expressing and 
Rb-deficient mice showed the same hyperplastic skin phenotype, suggesting additional 
regulation carried out by E7 in an Rb-independent manner (Balsitis et al., 2003). Additionally, 
E7 has also been reported to interact with transcription factors and co-regulators, including 
c-Jun (Antinore et al., 1996), chromatin remodelling enzyme p300 (Bernat et al., 2003), SKI-
interacting protein (Skip), (Prathapam et al., 2001) TATA-box binding protein (TBP) (Slebos 
et al., 1994) and proteasome (Wang et al., 2001).  
 
The tumour-inducing effects of “high risk” HPVs are largely attributed to the 
expression of E6 and E7 proteins. The functional inactivation of both p53 and Rb by E6 and 
E7, respectively, are necessary for carcinogenesis, as disabling either of them alone does 
not enable malignant transformation of primary cells in vitro (Munger et al., 1992; Thomas 
et al., 1999). E6 and E7 proteins also interfere with interferon secretion by interacting with 
IRF3 (Ronco et al., 1998) and IRF9 (Arany et al., 1995) respectively, and thus inhibit IFNα 
transcription. E7 also binds to IRF1 and prevents IFNβ promoter activation via recruitment 
of histone deacetylase to the IFNβ promoter (Park et al., 2000). Collectively, the low 
replication profile, dysregulation of cell cycle, and interference with interferon secretion 
during persistent high-risk HPV infection contribute to the formation, progression and 
immune evasion of HPV-induced cancers. According to this study, despite the fact that E7 
protein interacts with many cellular proteins other than Rb, it is very likely that E7-Rb 
interaction is the major cause of the suppressive local immunity.   
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Tumour microenvironment and immune suppression in epithelial cancer 
Tumour growth is greatly influenced by the microenvironment, where it creates 
communication between tumour and the immune system. Elucidating the immune 
modulation of tumour microenvironments and the balance between active and repressive 
immune responses have become a major focal point of tumour immunotherapy research. 
Several lines of evidence support that cancer patients have better prognosis when they 
present with tumour infiltrating lymphocytes (Clark et al., 1989; Clemente et al., 1996; Zhang 
et al., 2003). Tumour infiltrating T lymphocytes were shown to correlate with better prognosis 
in ovarian cancer (Zhang et al., 2003), melanoma (Clark et al., 1989; Clemente et al., 1996) 
and breast cancer (Mulligan et al., 2016). The anti-tumour immunity of T cells have been 
demonstrated in UV light-induced tumour, where the absence of T cells promoted their 
progressive growth (Ward et al., 1990). However, as tumours develop, they secrete factors 
to “educate” or prime infiltrating lymphocytes and alter their differentiation in favour of tumour 
development. In this case, tumour infiltrating T lymphocytes do not necessarily help 
eradicate tumour, but instead facilitate tumour growth and metastasis. For instance, transfer 
of antigen-specific CD4+ T cells into mutant Ras oncogene mice did not improve tumour 
eradiation but instead promoted tumour growth (Siegel et al., 2000). Depletion of intra-
tumoural CD4+ T cells was shown to be beneficial for tumour regression accompanied by 
improved cytotoxic CD8+ T cell activity (Awwad and North, 1988). In the study by Christopher 
T. et al., CD4+ T cells were shown to be responsive for peptide recognition when mutant 
Ras oncogene mice, which are cancer-prone mice, were immunised with mutant peptide. 
However, these mice failed to eradicate oncogene-expressing tumour cells (Siegel et al., 
2000). In an ovarian cancer study, tumour cells secrete CCL22 to recruit Foxp3+CD4+CD25+ 
Treg, which suppress tumour-specific T cell immunity and foster cancer growth (Curiel et al., 
2004). These studies suggest an existing regulatory CD4+ T cell (Treg) population is either 
recruited or being induced in the tumour microenvironment. 
 
In addition to T lymphocytes, myeloid cells infiltrate tumours and promote tumour 
progression though supporting tumour proliferation, angiogenesis and evading immune 
surveillance (Shojaei et al., 2009; Shojaei et al., 2007; Yang et al., 2004). Tumour infiltrating 
myeloid cells are immature CD11b+ myeloid cells differentiated from common myeloid 
precursors (CMP). Types of tumour infiltrated myeloid cells include: 1) tumour-associated 
macrophages (TAM), 2) Tie-2 expressing monocytes (TEM), 3) immature myeloid cells, and 
myeloid derived suppressor cells (MDSC) that show suppressive activities. More recently, 
tumour infiltrating myeloid cells are gaining better recognition as targets for cancer research 
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as they play important regulatory roles in bridging the tumour microenvironment and 
effective T cell responses. Thus, modulating the recruitment signals or blocking the 
downstream factors of these infiltrated cells may be important targets of cancer 
immunotherapy.  
 
Current development of HPV therapeutic vaccines: the promises and the needs 
Although prophylactic HPV vaccines are available, therapeutic vaccines for high risk HPV16 
and HPV18 are still in need to treat persistent infection and to prevent it from developing 
into cancer. To date, HPV therapeutic vaccination is aimed at boosting IFNγ secretion and 
cytotoxicity of CD8+ T cells by immunising with HPV viral antigens. Current therapeutic 
vaccine trials include three platforms: the protein/peptide based, viral vector based and the 
E7-DNA based platform. In all three platforms, pre-cancerous cervical intraepithelial 
neoplasia (CIN) patients showed more effective responses than cervical cancer patients 
(Morrow et al., 2013). The strategies and outcomes for each platform are discussed in this 
section. 
 
The general strategy of the protein/peptide vaccine platform involves linking the E7 
antigen to different pathogen proteins, such as Haemophilus influenza protein D (Corona 
Gutierrez et al., 2004), and HSP65 from Mycobacterium bovis (Einstein et al., 2007; Hallez 
et al., 2004). This is thought to invoke a greater response as a result of increased 
immunogenicity. After immunised with linked E7 antigen, vaccine-induced IFNγ production 
is increased in CD4+ and CD8+ T cells and lesion size is reduced by 50% (Einstein et al., 
2007). However, the total percentage of vaccinated patients that presented with regression 
is similar to the unvaccinated cohort (spontaneous regression). In a clinical study conducted 
by van der Burg and Melief et al. showed all recruited stage 3 vulvar intraepithelial neoplasia 
(VIN3) patients had IFNγ-associated proliferative CD4+ T cell responses and increased IFNγ 
production by CD8+ T cells after immunised with HPV16E6/E7 peptide (Kenter et al., 2009). 
At 12-months follow-up, 15 out of 19 patients had clinical responses. Although, similar 
approach was utilised for CIN2 and CIN3 therapeutic vaccine development, the vaccine 
response was mainly dominated by CD4+FOXP3+CD25+ regulatory T cells, suggested a 
necessity to overcome the inhibitory effects (Welters et al., 2008).  
 
One viral vector (modified vaccinia ankara, MVA) based therapy, targeting E2 antigen 
of HPV16 and 18, showed 37.5% of enrolled patients were HPV DNA negative after 
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treatment (Garcia-Hernandez et al., 2006). However, those patients also developed 
antibodies against the viral vector and recurrence of lesions was observed after the end 
point of treatment. The E7-DNA based platform showed a more promising effect with high 
percentage of patients with significant regression. Patients were immunised with plasmid 
DNA encoding similar sequence to E7 of HPV16. In these patients, there was no detectable 
HPV DNA and no histological disease phenotype upon completion of the therapy (Sheets et 
al., 2003). However, a major drawback in this trial was presented; the effects were restricted 
to patients expressing HLA-A2 haplotype. Another trial that targeted both E6 and E7 of 
HPV16/18 showed 18 out of 18 patients with antigen-specific antibody production in serum, 
as well as 10 out of 11 patients with increased cytotoxic T lymphocytes (Bagarazzi et al., 
2012). However, CD4+FOXP3+CD25+ Treg cells were also increased after receiving the 
vaccine, suggesting a possible factor that may impact on the therapeutic outcome. More 
recently, a DNA plasmid based therapeutic vaccine targeting HPV16/18 E6 and E7 (VGX-
3100) has shown promising results in a double-blind phase 2b clinical trial (NCT01304524) 
(more discussion on this vaccine can be found in chapter 4). The vaccine, although is 
significantly effective, having 40% of responders, there is 60% of participants who do not 
respond to the vaccination. This suggests that a general suppressive immune response 
plays important role in controlling the efficiency of immunotherapy and also that the 
individual variance may accounts for degree of responsiveness.  
 
As persistent HPV infection alters the epithelial environment and perturbs lymphocyte 
functions as a result of continuous antigen stimulation, it may be worth targeting 
suppressive/inhibitory factors or boosting positive immune responses induced in the altered 
epithelial environment as an alternative or complimentary therapeutic approach. This study 
focuses on the persistent high-risk HPV type 16 infection. The following chapters 
concentrate on the observations and impacts of E7 protein of the HPV16.  
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K14.E7 transgenic mouse as a model for persistent HPV infection   
Due to the lack of a representative in vitro model of HPV16 infection, animal models that 
exhibit the traits of persistent HPV16 infection were developed. Because HPV infection is 
highly species specific, an animal model that represents human HPV infection requires to 
circumvent this species specificity and to reflect the localised infection in the clinical setting. 
To mimic the tissue specific infection of HPV16, Lee et al. delivered HPV virus with LoxP 
flanking by adenovirus to create extrachromosomal viral replication after Cre recombinase 
excision (Lee et al., 2004). However, the LoxP flanking sites disrupted the long control region 
of the virus genome and thus was unable to rule out the possible effect that this region has 
on viral replication. The Frazer Lab utilizes a transgenic K14.E7 mouse, where expression 
of HPV16 E7 protein is driven by the keratin 14 promoter, as a study model for persistent 
HPV16 infection. The K14.E7 transgenic mice express E7 protein in both skin and thymus 
without the presence of autoimmunity to E7 (Malcolm et al., 2003) and show hyper-
proliferative epithelium with increased skin thickness (Herber et al., 1996). Although 
exhibiting increased epidermal thickness and lymphocyte infiltration in the skin, the 
hyperplastic K14.E7 transgenic mice do not progress to cancer in a C57BL/6 background. 
In fact, according to our RNA sequencing data, the mRNA expression profile in K14.E7 mice 
skin resemble the profile of human cervical intraepithelial neoplasia grade 3 (CIN3) (Tuong 
et al., 2018). Thus, the K14.E7 mouse model serves as a useful tool to study epithelial pre-
malignancy and the discovery and improvement of potential therapeutic strategies.  
 
K14.E7xRbΔL/ΔL as E7-expressing non-hyperplastic model 
The observed hyperplasia in K14.E7 skin is caused by the interaction between E7 and Rb, 
leading to dysregulated cell cycle control and hyper-proliferation. Deletion of Rb gene 
resulted in dysregulated cell cycle progression and failed to restore E7-expressing skin to 
normal physiology (Balsitis et al., 2005). Frederick et al. (Dick et al., 2000) first generated 
the mutated LXCXE motif of Rb protein (RbΔL/ΔL) and showed that this mutation keeps 
normal Rb function intact and does not interrupt E2F1-Rb interaction. The mutation mainly 
disrupts Rb-E7 interaction (Dick et al., 2000). Crossing RbΔL/ΔL mice with K14.E7 transgenic 
mice allows the identification of whether Rb-dependent or Rb-independent effect is required 
for E7-induced deregulation (Balsitis et al., 2005) (Figure 1.2). Inhibited proliferation of 
suprabasal cells in the skin of K14.E7xRbΔL/ΔL was observed when compared with K14.E7, 
suggesting that E7 accelerates epithelial proliferation in an Rb-binding-dependent manner 
(Balsitis et al., 2005). Moreover, infiltration of CD3+ T cell in the skin of K14.E7xRbΔL/ΔL was 
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reduced to a comparable level to syngeneic non-transgenic mouse (Choyce et al., 2013). 
This finding also suggests that T cell skin infiltration is an Rb-dependent function of HPVE7 
protein and possibly a result of epithelial hyperplasia. 
 
Figure 1.2. E7-Rb interaction disrupts normal cell cycle control  
(graph remade from (Brown et al., 2012; Dick et al., 2000)). 
In a normal cell cycle (C57BL/6), Rb protein interacts with transcription factor E2F1 during 
mid G1 phase to late G1 phase. Rb protein is gradually phosphorylated by cyclin-dependent 
kinases and will eventually release E2F1 after tri-phosphorylation. As a result, E2F1 can 
activate transcription and allow S phase entry for cell proliferation. The interaction between 
E2F1 is disrupted in the presence of E7 (K14.E7). E7-Rb interaction leads to Rb degradation 
and uncontrolled cell cycle progression. In the K14.E7xRbΔL/ΔL model, where the E7-Rb 
interacting site is mutated, Rb remains its normal function and therefore allows normal cell 
cycle progression even in the presence of E7. 
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Syngeneic immunocompetent mice do not reject K14.E7 skin grafts  
In response to general acute virus infection, antigen presenting cells migrate to drain lymph 
node where they present viral antigens and/or damage-associated molecular pattern 
(DAMP) as well as pathogen-associated molecular pattern (PAMP) to naïve lymphocytes. 
Primed T cells undergo activation and differentiation, which contribute to virus clearance 
and generate long-lived effector memory T cells (TEM) for tissue surveillance. DAMP and 
PAMP molecules can also serve as T cell attractants. Tissue resident T cells and TEM can 
be primed locally and will either proliferate or generate counteracting suppressive T cell 
subsets upon second or long-term infection.  
 
The Frazer lab utilises a skin grafting model to emulate persistent HPV infection. This 
is achieved by grafting the skin of K14.E7 mice onto syngeneic immune competent mice. 
Immune competent mice do not reject K14.E7 skin while rejection was observed for 
K5mOVA-expressing skin grafts, where a membrane-bound chicken ovalbumin is 
expressed under the control of keratin 5 promoter (Broom et al., 2010). Furthermore, 
rejection of K5mOVA skin grafts, but not K14.E7, can be accelerated with either transfer 
antigen-specific CD4+ T cells or substitution with CD40 co-stimulation (Broom et al., 2010). 
Rejection of E7-expressing skin graft can be enabled by Listeria monocytogenes infection 
(Frazer et al., 2001) or in combination with active immunisation plus transferring antigen-
specific CD8+ T cell (Matsumoto et al., 2004). These results indicate that the ability of 
effective CD8+ T cell responses and memory are either impaired or ineffective during 
persistent HPV16 infection.  
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Mechanisms that contribute to K14.E7 skin graft tolerance 
Ongoing efforts in the Frazer lab are focused on elucidating the underlying immunological 
mechanisms that prevent K14.E7 skin graft clearance. The main findings to date will be 
summarised in a concise fashion in the sections hereafter. A summary table of the current 
findings from the Frazer lab is shown below.  
 
Table 1.1. Summary of current findings that contribute to suppressive immune 
environment in K14.E7 skin  
Inducer/ 
recruiting 
signal 
Infiltrating and 
residing cells 
Secreted 
Factors 
Skin grafts 
rejected 
References 
IL-23; IL-1β CD4; γT cells IL-17 K14.E7xIL-17-/- (Gosmann 
et al., 
2014b) 
IL-18 NKT IFNγ K14.E7xJα18-/- 
K14.E7xCD1d-/- 
K14.E7x IFNγ -/- 
(Gosmann 
et al., 
2014a; 
Mattarollo 
et al., 
2010a; 
Mattarollo 
et al., 2011) 
IFNγ IFNγR-
expressing 
migratory DC 
Indoleamine 
2,3-
Dioxyehnase 
(IDO1)  
Inhibitor of IDO1 (1-
D/L-MT)  
accelerates K14.E7 
skin graft rejection 
(Mittal et 
al., 2013) 
CCL2, CCL5 
from 
Keratinocyte 
Mast cells 
 
K14.E7xKit w-sh/w-sh (Bergot et 
al., 2014) 
Ccr6  CD4+ T cells 
 
K14.E7xRAG-/- (Choyce et 
al., 2013) 
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? CD4+CD25+ Treg 
 
K14.E7xFoxP3-/- 
(K14.E7xDEREG) 
NOT REJECTED 
(Mattarollo 
et al., 2011; 
Narayan et 
al., 2009) 
? CD8+ T cells 
 
K14.E7xRAG-/- (Choyce et 
al., 2013) 
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Regulation of innate immunity of the K14.E7 skin  
Innate immunity mediates the first response towards foreign antigens through inducing 
inflammation. Secretion of pro-inflammatory cytokines such as IL-1β, IL-6 and TNFα is the 
main inducer of inflammatory responses. K5mOVA skin grafts were spontaneously rejected 
when grafted onto syngeneic background mice and accompanied with high level of IL-1β 
secretion (Hadis et al., 2010). Moreover, IL-1β signalling pathway was shown to be critical 
for K14.E7 skin graft rejection, as depleting the naturally occurring IL-1R antagonist, IL-1Ra, 
enabled rejection of K14.E7 skin grafts (Hadis et al., 2010). Despite the abundance of pro-
inflammatory cytokine secreted in K14.E7 skin, regulatory cytokine-IL-10 mRNA and protein 
expression are increased in cervical biopsies in association with cervical cancer progression 
(Bermudez-Morales et al., 2008). These findings suggest that pro-inflammatory cytokines 
and the balance between effector and regulatory cytokines are necessary to induce skin 
graft rejection in the context of keratin promoter driven antigens.  
 
Arginase is identified as a pro-inflammatory factor, contributing to allergic asthma 
(Maarsingh et al., 2009), retinal inflammation (Zhang et al., 2009), and the clearance of 
arthritogenic alphavirus (Stoermer et al., 2012). Acute inflammation after topical 2,4-
Dinitrochlorobenzene (DNCB) application was observed in the E7-expressing skin (Tran et 
al., 2014). Inhibiting arginase activity by Nω-hydroxy-nor-L-arginine ameliorates DNCB-
induced hyper-inflammation. Consistent with the previous finding, DNCB-induced hyper-
inflammatory skin exhibited higher level of IL-1β secretion. Infiltration of CD45+CD11b+ 
myeloid cells, and amplified Th2 cytokine production were observed after DNCB treatment, 
suggesting that myeloid cell activation contributes to arginase mediated inflammatory 
responses. Further identification showed a subset of myeloid cells, CD11b+ Gr1int F4/80+ 
Ly6C+Ly6Glow, is responsible for Arg-1 production in DNCB-treated skin (Tran et al., 2014). 
Arg-1 production is independent of T and B lymphocytes, as evidenced by no significant 
difference in Arg-1 expression between K14.E7 and K14.E7xRag-/- mice, where no T cells 
and B cells exist in the latter (Tran et al., 2014). Depletion of IL-17 abolished DNCB-induced 
Arg-1 production and hyper-inflammation, indicating that IL-17 is the key inducer of Arg-1 
(Tran le et al., 2015). Taken together, local determinants, such as IL-1β, Arg-1 and IL-17, 
control the outcome of K14.E7 skin grafts and inflammatory response towards topical 
immune therapies.  
 
In addition to myeloid cells, mast cells were recruited by CCL2 and CCL5 in the 
K14.E7 skin and displayed increased degranulation (Bergot et al., 2014). Skin grafts from 
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K14.E7 mice crossed with mast cell depleted Kit w-sh/w-sh mice were rejected within three 
weeks (Bergot et al., 2014). This suggested that mast cells play an immune suppressive 
role in HPV16E7-expressing skin.  
 
NKT cells mediate the outcome of K14.E7 skin grafts 
Cells that control the bridging between innate and adaptive immune activation were also 
identified to play inhibitory roles in K14.E7 skin. These cells include Natural Killer T cell 
(NKT) and dendritic cells. NKT cells are T cells that can only be activated by antigens 
presented on CD1d molecule and have been shown to have profound impact towards 
immune regulation in both inducing cytotoxic immune responses and protection against 
foreign antigens (Godfrey and Kronenberg, 2004 and references therein).  
 
NKT cells act as an immune response suppressor in the persistent HPV16 infection 
model. E7-expressing but NKT-deficient (CD1dKO or Jα18KO) skin grafts were rejected by 
immune competent mice (Mattarollo et al., 2010a). In contrast to the known cytotoxic 
function, IFNγ produced by NKT cells was found to be critical for K14.E7 skin graft tolerance. 
CD1d-expressing CD11C+F4/80hi population are responsible for activation of the NKT cells 
and secretion of IFNγ in the skin graft (Mattarollo et al., 2010a). However, the signals that 
recruit CD11C+F4/80hi population to the site of skin graft have not yet been characterised. 
Further investigations demonstrated that the secretion of IFNγ in E7-expressing skin is 
induced by IL-18, rather than IL-12 (Gosmann et al., 2014a). Taken together, in the K14.E7 
mouse model, NKT cells contribute to the immune suppressive environment by secreting 
IFNγ and impair effective antigen-specific CD8+ T cell function (Mattarollo et al., 2010b).  
 
Impaired antigen presenting ability of dendritic cells and keratinocytes in K14.E7 skin  
Skin dendritic cells (DCs) serve as a first line responsive cell type that present pathogens 
and control the immunogenicity of vaccines to induce either effector immune response or 
tolerance. Upon activation, dendritic cells migrate to draining lymph node and present 
antigens along with co-stimulatory molecules to antigen-specific T cells. In normal skin, 
Langerin (CD207)-positive Langerhans cells (LCs) are the predominant dendritic cell type in 
the epidermis. In the dermis layer, migrating LCs, CD11b+ DC, CD103+ DC and 
CD207/CD11b double negative DCs comprise the whole dermal DC population (Heath and 
Carbone, 2009). Cutaneous expression of HPV16E7 alters the proportion and the ability of 
antigen presenting cell (APC) subtypes in the skin and thus contributes to differential 
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adaptive immune responses (Chandra et al., 2016). Migratory DC populations 
(CD11c+MHCIIhi) were found to have increased IFNγR expression, receiving the elevated 
IFNγ signal from the E7-expressing skin, and to produce indoleamine 2,3-Dioxyehnase 
(IDO1) that induces K14.E7 graft tolerance (Mittal et al., 2013). DCs in the K14.E7 skin were 
demonstrated to have enhanced migration to the draining lymph nodes but impaired antigen 
processing ability (Chandra et al., 2016). Moreover, LC in the K14.E7 skin showed reduced 
MHCII expression and increased immune modulatory factor secretion, including IDO1, Arg-
1, IL-10, IL-6, IL-12 and IL-23p40 (Chandra et al., 2016). In addition to professional antigen 
presenting cells, the ability of keratinocyte to present antigens through MHCI to CD8+ T cells 
was inhibited in E7-expressing keratinocytes (Zhou et al., 2011). While IFNγ stimulation 
enhanced the susceptibility of OVA-expressing keratinocytes to T cell lysis through up-
regulated MHCI expression, E7-expressing keratinocytes failed to be lysed under the same 
stimulation (Zhou et al., 2011). Together, antigen presenting process in both professional 
antigen-presenting cells (APC)s and keratinocytes is dysregulated and impaired in the 
K14.E7 skin.  
 
Suppressive adaptive immune response in K14.E7 skin 
The K14.E7 hyperplastic skin is highly infiltrated with proliferative CD4+ and CD8+ T 
lymphocytes when compared with wild type non-transgenic mice, suggesting that the skin-
infiltrating lymphocytes contributes significantly to the immune regulation. Therefore, the 
ineffective T cell responses in the K14.E7 skin has been largely attributed to 
irresponsiveness of peripheral CD8+ T cells, elevated regulatory T cell responses and 
regulatory cytokines. In the transgenic K14.E7 mice, the responsiveness of peripheral CD8+ 
T cells to E7 or to other antigens that are not related to E7 are dampened, while CD4+ T 
cells and antibody production are not affected (Narayan et al., 2009). This suppressive CD8+ 
T cell response could be mediated by CD4+CD25+ Treg cells as neutralising either CD4+or 
CD25+ restores CD8+ T cell response (Narayan et al., 2009). However, as neutralising 
antibody used in the study was not specific to Treg cells but the whole CD4+ or CD25+ T cell 
population, contribution of Treg cells in mediating the ineffective response should be further 
evaluated. Moreover, depleting FoxP3+ regulatory T cells in either K14.E7 donors or 
recipients did not enable graft rejection, suggesting that FoxP3+ Treg cells alone is not 
sufficient to induce the immune suppressive environment in K14.E7 skin (Mattarollo et al., 
2011).  
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Pro-inflammatory cytokine-IL-17, secreted by CD4+ T cells and γδ T cells under the 
stimulation of IL-23, plays a suppressive role in the context of E7-expressing epithelium. 
Skin grafts of K14.E7xIL-17-/- mice were enabled for rejection (Gosmann et al., 2014b), 
suggesting IL-17 as a critical factor determining the suppressive local immune environment.  
 
The chronic inflammation and the recruitment of innate immune cells to the 
inflammatory site were shown to be B lymphocyte-dependent in a K14-HPV16 (express both 
E6 and E7 protein of HPV16) mouse model (de Visser et al., 2005). Although there is no 
significant B lymphocyte infiltration in the hyperplastic skin, the immunoglobulin deposition 
was observed (de Visser et al., 2005). Repopulation of B cells into K14HPV16 Rag-/- mice 
restored the malignancy phenotype, with skin hyperplasia and increased infiltration of mast 
cells and Gr1+ cells (de Visser et al., 2005).  
 
In summary, K14.E7 model mimics the late stage of epithelial tumorigenesis, where 
innate, adaptive and regulations between innate-adaptive immunity all contribute to the 
immune suppressive environment. However, how lymphocytes are recruited to the skin and 
the initiator for suppressive immune response are not yet fully understood. To date, only one 
study has suggested a possible mechanism that may mediate the T cell recruitment to E7-
expressing skin. In the study by Choyce et al., it was found that CD4+ T cells in the K14.E7 
skin expressed higher levels of CCR6 when compared to CD4+ T cells within the draining 
lymph nodes (Choyce et al., 2013). Together with K14.E7xRbΔL/ΔL, this study aims to 
understand to what extend the E7-Rb interaction contributes to the immune responses in 
the context of cutaneous HPV16E7 expression.  
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Chemokine and Chemokine receptors 
One focus of this study investigates on the recruitment of T lymphocytes to the hyperplastic 
K14.E7 skin. This line of study is based on the results of the whole skin RNAseq analysis 
presenting in Chapter 2. An overview of chemokines and the receptors is presented in this 
section.  
 
Chemokines are small secreted chemotactic cytokines ranging from 8-14kDa and are 
classified into four groups based on the position of the conserved cysteine residues: CXC, 
CC, C and CX3C (Zweemer et al., 2014). They typically interact with chemokine receptors, 
which are seven-transmembrane receptors (7TMR) of the GPCR superfamily (Proudfoot, 
2002), and carry out diverse signal transmission to direct leukocyte migration, inflammation 
and differentiation (Luster, 1998; Stoolman, 1989). The importance of chemokines and 
chemokine receptors in regulating inflammatory processes is underpinned in their 
involvement in the pathogenesis of several autoimmune diseases, including rheumatoid 
arthritis (Koch, 2005; Yellin et al., 2012), inflammatory bowel disease (McGuire et al., 2011), 
type I diabetes (Frigerio et al., 2002; Shehadeh et al., 2009) and psoriasis (Antonelli et al., 
2008; Harper et al., 2009) 
 
Multiple chemokines can interact with the same chemokine receptor resulting in 
functional redundancy in some cases, in a phenomenon termed by Robert J. Lefkowitz as 
biased signalling (Reiter et al., 2012; Samama et al., 1993). However, there are exceptions 
to this: CXCR4, CXCR5, CXCR6, CCR6, CCR9 and CX3CR1 only have one specific ligand 
(Zweemer et al., 2014). The selective ligand binding accounts for tissue specific and cell 
type specific lymphocyte recruitments. For example, CCR9 plays critical role in recruiting 
lymphocytes to the gut (McGuire et al., 2011) and CCR6 drives Th17 homing to the site of 
inflammation (Reboldi et al., 2009). 
 
More recently, chemokines have been observed to have functions aside from being 
leukocyte attractants. Nathan Karin and Gizi Wildbaum termed chemokines that are able to 
alter the biological functions of the recruited lymphocytes as driver chemokines (Karin et al., 
2015). Like cytokines, which are well-studied signals that direct T cell differentiation and 
polarisation, driver chemokines have been shown to have similar role. For example, 
CXCL12 polarizes CXCR4+ macrophages to IL-10 secreting M2-like macrophages (Martinez 
et al., 2008) and CXCR4+CD4+ T cells to IL-10 producing regulatory T cells (Tr1) that 
suppress experimental autoimmune encephalomyelitis (EAE) (Meiron et al., 2008). Apart 
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from inducing immunosuppressive cell types, chemokine signallings can influence effector 
T cell polarization. For instance, CXCL10 has been demonstrated to direct effector T cell 
polarisation (Salomon et al., 2002; Wildbaum et al., 2002). CXCL9 and CXCL10 together 
drive Th1 and Th17 polarization through STAT1, STAT4 and STAT5 phosphorylation 
dependent pathway.  
 
Previous studies in the Frazer lab have identified several chemokine and chemokine 
receptor signalling pathways to mediate the recruitment of infiltrating lymphocytes in the 
thickened skin of K14.E7 transgenic mice. We have established that the E7 induced 
epithelial hyperplasia is associated with i) increased epidermal secretion of Ccl2 and Ccl5 
and consequent recruitment of mast cells (Bergot et al., 2014), ii) increased expression of 
potent neutrophil chemoattractants including Cxcl1, Cxcl2 and Cxcl5 in DNCB-treated 
K14.E7 skin (Tran le et al., 2015), and iii) expression of Ccr6, the receptor for chemokine 
Ccl20, on CD4+ T cells in K14.E7 skin is higher than lymph node of K14.E7 (Choyce et al., 
2013). Although we have explored the relationship between several chemokines and 
immunocyte recruitment in K14.E7 skin, the epithelial hyperplasia-directed, as well as the 
degree of contribution of the E7-Rb interaction to lymphocyte-recruiting signal have not yet 
been understood.  
  
The remainder of this literature review will focus on CXCR3 and its interacting ligands 
as results (see Chapter 2) indicate their involvement in E7-Rb interaction-associated skin 
hyperplasia. As IFNγ production is enriched in K14.E7 skin environment and could serve as 
a potent inducer for CXCL9 and CXCL10 secretion by keratinocytes, we hypothesise that 
CXCR3 chemokine receptor pathway is important for the recruitment of T cells in the K14.E7 
hyperplastic environment. 
 
CXCR3 and ligands 
CXCR3 is primarily expressed on activated T cells and NK cells (Qin et al., 1998). Co-
expression of CXCR3 and CCR5 mark the Th1 subsets (Qin et al., 1998), while CCR3 and 
CCR4 are preferentially expressed on Th2 subsets (Sallusto et al., 1998). Examples of 
CXCR3 functions include: i) the recruitment of activated Th1 cells to inflamed tissues 
(Campanella et al., 2008; Khan et al., 2000; Xie et al., 2003), ii) the regulation of skin-homing 
autoreactive CD8+ T cells in graft-versus-host-disease (GVHD) (Villarroel et al., 2014), and 
iii) the rapid recruitment of NK cells to antigen-stimulated lymph node and facilitation of Th1 
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subset priming (Martin-Fontecha et al., 2004). Transcription factor T-bet, the master 
regulator controlling Th1 and CTL polarization, is also a direct trans-activator of CXCR3 
expression (Lord et al., 2005). T-bet deficient mice have limited Th1 infiltration to the 
inflamed tissue, while reconstitution of Cxcr3 expression in T-bet-/- mice was able to re-
balance the defect (Lord et al., 2005). Apart from effector cells, Cxcr3 is also expressed on 
Foxp3-positive regulatory T cells. Foxp3 up-regulates T-bet and in turn induces the 
expression of Cxcr3 on Foxp3-positive regulatory T cells. This allows accumulation of Treg 
at sites of Th1-mediated inflammation and maintains the homeostasis of Th1 responses 
(Koch et al., 2009). 
  
CXCR3 ligands include CXCL9 (monokine induced by gamma interferon, MIG), 
CXCL10 (interferon gamma-induced protein 10, IP-10) and CXCL11 (interferon-inducible T-
cell alpha chemoattractant, I-TAC). The expression of these three ligands depends on 
interferon induction (Groom and Luster, 2011). Furthermore, they have different binding 
affinity with CXCR3, where CXCL11 has the highest affinity and CXCL10 is higher than 
CXCL9 (Groom and Luster, 2011). This binding discrepancy among ligands may accounts 
for the counteracting and cooperating effects of the CXCR3 signalling pathway. In most 
cases, CXCL9 and CXCL10 induce effective immune response after interacting with 
receptors on T cells, while CXCL11 induces suppressive immune response (Groom and 
Luster, 2011). For example, CXCL11 was shown to be required for inducing FOXP3-IL-10hi 
CD4+ Tr1 cells (Zohar et al., 2014). However, it should be noted that C57BL/6 mice are 
genetically deficient in Cxcl11 gene expression due to the generation of a premature stop 
codon within the Cxcl11 transcript. Thus Cxcl11 protein expression is attenuated in C57BL/6 
mice (Groom and Luster, 2011). 
 
The redundancy of Cxcr3 ligands for T cell-recruitment has been demonstrated in a 
murine model of obliterative bronchiolitis (Medoff et al., 2006). They showed that even 
though Cxcl9 and Cxcl10 are induced and are required in a different manner and the 
expression level peaked at different stages during allogeneic transplant, in which neither 
Cxcl9-/- nor Cxcl10-/- animal showed significant recovery of rejection (Medoff et al., 2006). 
Apart from redundancy, CXCR3 ligands have been shown to have synergistic and 
cooperative effects. For example, CXCR3 ligands cooperatively induce activated T cell 
recruitment and generation of CTLs (Yoon et al., 2009) and also the recruitment of NK cells 
and CTLs to the spinal cord during herpes simplex virus-2 infection (Thapa et al., 2008). In 
some cases, CXCR3 ligands showed counteracting effects. This is seen in a murine MHC-
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mismatched cardiac transplantation model, where Cxcl9 and Cxcl10 showed antagonistic 
effect towards priming of the donor-reactive T cells (Rosenblum et al., 2010). The absence 
of Cxcl9, in recipient, donor or both, down-regulate the frequency of donor-reactive IFNγ-
producing CD8 T cells. On the contrary, donor-reactive IFNγ-producing CD8 T cells 
increased in the absence of Cxcl10 in a Cxcl9-dependent manner (Rosenblum et al., 2010). 
Although the physiological effect of CXCR3 signalling pathway has been extensively 
studied, there are limited investigations on how this signal is involved in the context of 
persisting cutaneous HPV infection. This study aims to decipher the degree of involvement 
of this pathway in HPV infection using transgenic K14.E7 mouse model.  
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1.2 Project Significance 
 
We have an established mouse model, K14.E7 that mimic the pre-cancerous lesions 
associated with persistent HPV16 infection. As the HPV16 E7 protein interacts with tumour 
suppressor gene Rb and disrupts normal cell cycle, E7 expression in keratinocytes is 
typically associated with hyperproliferation of the epithelium. Previous studies in the Frazer 
lab have shown that the hyperproliferative skin phenotype accompanied with increased 
number of immune cell infiltration, defective antigen presentation, increased regulatory 
cytokine secretion and suppressed immune response in K14.E7 skin (Gosmann et al., 
2014a; Hadis et al., 2010; Mattarollo et al., 2010a; Mittal et al., 2013). However, whether 
these observed phenotypes and immune responses in K14.E7 skin are the result of viral 
oncogene E7 expression or the E7-Rb interaction-induced hyperplasia is not yet understood.  
 
These effects may potentially be delineated using a mutant Rb expressing mouse 
model that results in the disruption of E7-Rb interaction, without affecting normal Rb function 
(RbΔL/ΔL). Double transgenic mice bearing K14.E7 and mutant Rb expression 
(K14.E7xRbΔL/ΔL) will enable us to differentiate the effects caused by E7 expression and E7-
Rb interaction-induced hyperplasia. With the K14.E7xRbΔL/ΔL mouse model, we will be able 
to identify potential new and/or novel targets that are dependent on E7-Rb interaction. These 
findings may aid in facilitating the development of better HPV16 therapeutic vaccines for the 
treatment of pre-cancerous epithelial lesions.  
 
1.3 Hypothesis and aims 
 
HPV16E7-Rb interaction-induced hyperplastic skin environment is responsible for 
suppressive immune responses in HPV16E7 pre-cancerous lesion. 
 
This study includes the following aims: 
Aim1: Characterization of K14.E7RbΔL/ΔL mice in the aspects of skin phenotypes and 
general immune responses  
Aim2: Investigate the mechanisms involved in K14.E7 skin infiltrating T cells and if 
the infiltration requires E7-Rb interaction-induced hyperplasia.  
Aim3: To find out if K14.E7RbΔL/ΔL skin graft can be rejected when grafted onto 
syngeneic background mice. If so, what are the mechanisms? If not, what are the 
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possible factors involved in the immune suppressive environment in addition to E7-
Rb interaction-induced hyperplasia.  
     22 
 
Chapter 2 
 
 
 
 
 
HPV16E7 induced hyperplasia promotes 
CXCL9/10 expression and induces CXCR3+ T cell 
migration to Skin
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2.1 Preface 
The results in this chapter cover aim one and two of the whole project. In this article, we 
characterized the skin of K14.E7x RbΔL/ΔL in terms of immune cell subsets, identified 
chemokines CXCL9/10 secreted from the hyperplastic K14.E7 skin using RNA sequencing 
and further functionally annotated the contribution this particular chemokine pathway to the 
fate of the K14.E7 skin graft. This article highlights, for the first time, a T lymphocyte 
population that contribute positively to skin graft rejection. This chapter was published as an 
original research article online on December, 2017 in Journal of Investigative Dermatology.   
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2.3 Abstract 
Chemokines regulate tissue immunity by recruiting specific subsets of immune cells. Mice 
expressing the E7 protein of HPV16 as a transgene from a keratin 14 promoter (K14.E7) 
show increased epidermal and dermal lymphocytic infiltrates, epidermal hyperplasia and 
suppressed local immunity. Here, we show that CXCL9 and CXCL10 are overexpressed in 
non-haematopoietic cells in skin of K14.E7 mice when compared with non-transgenic 
animals, and recruit CXCR3+ lymphocytes to the hyperplastic skin. Overexpression of 
CXCL9 and CXCL10 is not observed in E7 transgenic mice with mutated Rb gene whose 
protein product cannot interact with E7 (K14.E7xRbL/L) and in consequence lack 
hyperplastic epithelium. CXCR3+ T cells are preferentially recruited by CXCL9 and CXCL10 
in supernatants of K14.E7 but not K14.E7xRbL/L skin cultures in vitro. CXCR3 signalling 
promotes infiltration of a subset of effector T lymphocytes that enables donor lymphocyte 
deficient, E7-expressing skin graft rejection. Taken together, this suggests that recruitment 
of CXCR3+ T cells can be an important factor in the rejection of precancerous skin epithelium 
providing they can overcome local immunosuppressive mechanisms driven by skin-resident 
lymphocytes. 
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2.4 Introduction 
Cervical intraepithelial neoplasia (CIN) is caused by persisting infection of the cervix with 
high-risk human papilloma virus (HPV). HPV infection often evades immune surveillance by 
various mechanisms (Hasan et al., 2013; Natale et al., 2000; Pacini et al., 2015; Tindle, 
2002). Although administration of therapeutic HPV vaccines, including peptide, protein or 
dendritic cell based vaccines, to patients with cervical intraepithelial neoplasia (CIN) have 
been associated with disease regression in several clinical trials (Hallez et al., 2004; Natale 
et al., 2000; Van Doorslaer et al., 2010), the rate of regression is not significantly greater 
than what occurs without intervention (Morrow et al., 2013). In addition, induction of CD4+ 
and CD8+ T cell responses after administration of HPV16 E6 and E7 peptides had been 
accompanied with a concomitant induction of inhibitory immune responses, negating 
potential therapeutic effects (Welters et al., 2008).  
 E7 is a papillomavirus encoded oncoprotein that disrupts regular cell cycle by 
interacting with and facilitating degradation of the Rb protein (Brown et al., 2012), leading to 
hyperproliferation of E7 expressing epithelial cells. A transgenic mouse model expressing 
HPV16 E7 viral protein under the control of keratin 14 promoter (K14.E7) has been 
generated to mimic persistent HPV epithelial infection (Herber et al., 1996). K14.E7 mouse 
skin shows disrupted keratinocyte differentiation with increased expression of stress 
keratins (6, 16 and 17) (Zhussupbekova et al., 2016) and high numbers of skin-infiltrating 
lymphocytes, resembling observations in human CIN lesions (Adurthi et al., 2008; Carrero 
et al., 2009; Kobayashi et al., 2008). Although K14.E7 skin graft is tolerated when grafted 
onto syngeneic immunocompetent recipients (Frazer et al., 2001; Matsumoto et al., 2004), 
removal of T cells from E7-expressing hyperplastic skin significantly enhances rejection of 
E7 transgenic skin grafts from immune competent recipients (Choyce et al., 2013) 
suggesting the presence of immunosuppressive lymphocytes within the K14.E7 skin 
environment.  
Chemokines direct leukocyte migration and differentiation (Luster, 1998; Stoolman, 1989) 
and also direct cytotoxic lymphocyte infiltration to tumour sites (Balkwill, 2004; Chow and 
Luster, 2014; Mantovani et al., 2004; Spranger et al., 2017). However, tumour infiltrating 
lymphocytes may contribute to the immunosuppressive environment and thus facilitate 
tumour growth, survival and metastasis (Balkwill, 2003). Clinical trials targeting chemokine 
inhibition have reported promising results against HIV infection (Muniz-Medina et al., 2009; 
Watson et al., 2005; Wood and Armour, 2005) and peripheral and cutaneous T cell 
lymphoma (Ishii et al., 2010; Satoh et al., 2006). An increased expression of CCR6 by CD4+ 
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T cells (Choyce et al., 2013) and mast cell recruitment by CCL2 and CCL5 (Bergot et al., 
2014) has been demonstrated in E7 transgenic skin.  
Here, we show that immune cell infiltration to E7 transgenic skin is a consequence of 
epidermal hyperplasia, and that hyperplasia induces CXCL9 and CXCL10 production to 
recruit a subset of CXCR3+ T cells, promoting rejection of grafted E7 transgenic skin 
depleted of immunosuppressive lymphocytes. Consequently, hyperplastic skin causes the 
infiltration of both suppressive and functional lymphocytes and the balance of these two 
subsets determines the fate of K14.E7 skin grafts.  
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2.5 Results 
E7 interaction with Rb protein is necessary to attract T cells to E7 transgenic skin  
K14.E7 transgenic mouse skin exhibits an immune cell infiltrate and regulatory cytokine 
production (Chandra et al., 2016; Choyce et al., 2013; Gosmann et al., 2014a; Gosmann et 
al., 2014b; Mattarollo et al., 2010b; Tran le et al., 2015). To determine whether the 
lymphocytic infiltrate observed in E7 transgenic skin requires interaction of E7 with Rb 
protein, we utilized a double transgenic mouse model expressing HPV16 E7 and a mutant 
Rb (K14.E7xRbL/L) that fails to bind E7 and therefore lacks epithelial hyperplasia without 
perturbing other Rb functions (Balsitis et al., 2005; Dick et al., 2000). The double transgenic 
mouse has equivalent expression of E7 mRNA to K14.E7 mice (Figure 2.1a). We compared 
skin immunocytes from female K14.E7 and K14.E7xRbL/L mice (RbL/L and C57BL/6 mice 
as controls). K14.E7 skin, but not K14.E7xRbL/L skin, demonstrated increased numbers of 
CD45+ lymphocytes, CD11b+ non-dendritic cell (DC) cells, CD4+ and CD8+ T cells (Figure 
2.1b, d and e). Moreover, decreased numbers of epidermal and dermal Langerhans cells 
(LCs), and higher proportions of epidermal and dermal CD11b+ DC, were observed in 
K14.E7 skin when compared with non-transgenic skin (Figure 2.1c). The numbers and types 
of antigen presenting cells in K14.E7xRbL/L skin were similar to skin from non-transgenic 
animals. Keratinocytes in K14.E7 skin showed increased major histocompatibility complex 
II (MHC II) expression, a finding consistent with keratinocyte activation in many inflammatory 
skin diseases (Bjerke, 1982; Gawkrodger et al., 1987; Lampert et al., 1982; Poulter et al., 
1982), whereas this was not observed in K14.E7xRbL/L or non-transgenic skin (Figure 
2.1f). In contrast to the skin findings, the percentages of lymphocyte subsets in the spleen 
of each transgenic line and non-transgenic animals were similar (Figure S2.1b).  
 
Taken together, these results suggest that E7 induced hyperplasia is mediating the 
immune cellular infiltrates that typifies hyperplastic E7-transgenic skin. 
 
Gene expression profiling of E7 transgenic skin  
Transcriptome analysis of skin of C57BL/6, K14.E7 and K14.E7xRbL/L was performed to 
understand the signals produced in the hyperplastic skin environment that promote immune 
cell recruitment. Differentially expressed genes (Benjamini–Hochberg P-value<0.01 and 
log2 fold-change>2) in K14.E7, K14.E7xRbL/L and non-transgenic animals (group A, B and 
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C) were identified using the LIMMA-voom R package (Figure S2.2e). Genes identified with 
group A and C but not group B (n=482) could thus be associated with skin hyperplasia. 
 
Gene ontology analysis (DAVID 6.8, KEGG) identified that the immune cell 
recruitment signals associated with cell adhesion and chemokine signalling were highly 
correlated with skin hyperplasia (n=482) (Figure 2.2a). Expression of genes encoding 
chemokines and chemokine receptors was up-regulated in K14.E7 skin but not in C57BL/6 
nor in K14.E7xRbL/L skin (Figure 2.2b). As elevated production of IFNγ is observed in E7 
transgenic skin (Gosmann et al., 2014a), and chemokines CXCL9 and CXCL10 are induced 
by Type 1 and 2 interferons and attract CXCR3+ T cells, we examined the correlation 
between the CXCR3 pathway signature in K14.E7 and non-transgenic skin using the 
Pathway Interaction Database (PID), curated for pre-ranked GSEA analysis. The 
transcription profile of K14.E7 skin was positively correlated with the CXCR3 pathway 
signature, while the transcription signatures of K14.E7xRbL/L and non-transgenic skin both 
showed a negative correlation (Figure 2.2c). Up-regulation of the CXCR3 gene set in K14.E7 
skin was also observed in CAMERA and ROAST analysis (Table S2.1).  
 
CXCL9 and CXCL10 are expressed on CD45- cells in hyperplastic K14.E7 epidermis  
Gene expression analysis suggested that CXCL9/10 chemokine production might contribute 
to CXCR3+ immune cell recruitment in hyperplastic skin. Consistent with this hypothesis, we 
observed that CXCR3+ CD4+ but not CXCR3+ CD8+ or CXCR3+ CD4-CD8- TCRβ+ T cells 
were increased in skin but not spleen from K14.E7 animals, when compared to 
K14.E7xRbL/L animals (Figure 2.3a-d). CXCR3+ CD4+ T cells from skin draining lymph 
nodes from K14.E7 mice are not activated when compared with cells from non-transgenic 
mice (Figure 2.3e). qPCR confirmed up-regulation of Cxcl9/10 mRNA expression in skin but 
not spleen from K14.E7 animals when compared with K14.E7xRbL/L or non-transgenic 
animals (Figure 2.4a). Flow cytometric analysis showed that cells in the epidermis of K14.E7 
mice express more CXCL9/10 (Figure 2.4b and c) than epidermal cells from K14.E7xRbL/L 
and non-transgenic mice, and that the majority of CXCL9/10 expression in K14.E7 epidermis 
was by CD45- cells (Figure 2.4d and e) and was dependent on IFNγ signalling (Figure S2.3a 
and b). Similarly, whole skin RNAseq showed reduced expression of Cxcl9 mRNA in E7 
transgenic animals lacking the IFNγ receptor (Figure S2.3c). DCs (gated on 
CD11c+MHCII+CD45+) of K14.E7 epidermis, express low to negative level of CXCL9 and 
CXCL10 when compared to the DCs from non-transgenic skin (Figure S2.4). 
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Immunofluorescent staining showed that in K14.E7 skin, the expression of CXCL10 was 
particularly prevalent at the basal layer of the epidermis and amongst fully differentiated 
keratinocytes, whereas CXCL9 was expressed uniformly in the suprabasal region of the 
epidermis (Figure 2.4f). Although some MHCII+ cells from the dermis of K14.E7 express 
CXCL9 and CXCL10 (Figure 2.4g), most expression appeared to be in MHCII- cells in the 
epidermis.  
 
CXCR3 promotes T lymphocyte recruitment to E7-associated hyperplastic skin 
To assess whether T cell migration to hyperplastic skin was dependent on CXCR3, an in 
vitro chemotaxis trans-well assay was performed, using T cells induced to express CXCR3 
(Nakajima et al., 2002). Supernatant from skin explants from K14.E7 mice attracted 
significantly more CXCR3+ CD4 and CD8 T cells (Figure 2.5a and b) than supernatant from 
K14.E7xRbL/L or non-transgenic skin. Moreover, CXCR3+ T cell migration was significantly 
reduced by a CXCL9/10 neutralising antibody (nAb) (Figure 2.5a-c), confirming a role for 
CXCL9 and CXCL10 in T cell migration in this assay. No significant CXCR3+ T cell migration 
was observed with supernatant from mice unable to express IFN- (K14.E7xIFNγ-/-; IFNγ-/-), 
supporting the hypothesis that CXCL9 and CXCL10 production is IFN- dependent. 
Expression of CXCR3 on migrated CXCR3+ T cells was lower on cells that migrated in 
response to K14.E7 skin supernatant (Figure 2.5c), suggesting internalization of ligand-
engaged receptors.  
 
CXCR3 signalling is required for T cell subset infiltration into K14.E7 skin grafts 
To further assess the role of CXCR3 chemokine signals in the recruitment of lymphocytes 
to K14.E7 skin in vivo, CXCR3+ T cells, derived from CD45.1+ congenic B6.SJL.Ptprca mice, 
were transferred to non-transgenic CD45.2+ animals bearing well healed CD45.2+ K14.E7 
grafts. Graft recipients were subsequently administered a CXCR3 antagonist-AMG487 or 
vehicle control (Figure 2.5d). Skin grafts harvested after four days of AMG-487 treatment 
had less TCRβ+ CD45.1+ cells (~30 cells per cm2 of skin graft) when compared to vehicle 
controls (~60 cells per cm2 of skin graft). Numbers of endogenous CD45.2 cells in the grafts 
were not altered by AMG-487 treatment (Figure 2.5e). Moreover, no significant difference in 
CD45.1+ T cell infiltration was found in lymph node or spleen of grafted animals (Figure 2.5f). 
The data shows that engagement of CXCR3 is required for a subset of T cells to localize in 
K14.E7 transgenic skin.  
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Antagonizing CXCR3 signal does not enable K14.E7 skin graft rejection 
Skin grafting was performed to investigate the function of skin infiltrating CXCR3+ T cells in 
the context of K14.E7 skin hyperplasia. K14.E7xRag-/- skin grafts were shown to be 
spontaneously rejected (Choyce et al., 2013) and produce chemokines CXCL9 and CXCL10 
(Figure 2.6a). Interestingly, while the dominant CD45- cell population in the epidermis of 
K14.E7xRag-/- mice produces minimal CXCL9/10, a small CXCL9/10-producing 
subpopulation that is not seen in K14.E7xIFNγ-/- mice is observed. This, therefore, may not 
be IFNγ induced. B6.SJL.Ptprca mice receive K14.E7 and K14.E7xRag-/- skin 7 days after 
recipients were immunized with E7 peptide. Grafted mice were treated with the CXCR3 
antagonist-AMG487 or vehicle control (Figure 2.6b). Host-derived CXCR3+ T cells were 
recruited to skin grafts in small numbers in vehicle control mice, but were largely absent in 
mice treated with the antagonist (Figure 2.6c). More CD4+CXCR3+ than CD8+CXCR3+ cells 
were recruited to K14.E7 skin graft (Figure 2.6d), consistent with the higher frequency of 
CD4+CXCR3+ cells found in the skin of K14.E7 (Figure 2.3a). K14.E7xRag-/- skin grafts were 
rejected (defined as 50% of skin graft shrinkage) when the recipient mice were administered 
with vehicle control, but were not rejected when treated with CXCR3 antagonist. K14.E7 
skin grafts onto C57BL/6 recipients were tolerated in both groups as previously shown 
(Figure 2.6e-f). This suggests that infiltrating CXCR3+ T cells are an effector population that 
is required for graft rejection in donor lymphocyte deficient skin grafts. Therefore, in the 
absence of donor lymphocyte mediated suppression, CXCR3+ effector T cell populations 
are able to effect skin graft rejection.  
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2.6 Discussion 
In this manuscript, we utilized K14.E7xRbL/L mice, which resembles normal skin in immune 
landscape and gene expression profile, to separate the hyperplastic phenotype from the 
local HPV16 E7 expression. We demonstrated that epithelial hyperplasia induced by 
HPV16E7 protein expression is required for the infiltration of immunocytes and the induction 
of CXCL9 and CXCL10 chemokines, which can attract CXCR3+ T cells to the skin. These 
findings pose two questions: firstly, how does the epithelial hyperplasia impact on infiltrated 
lymphocytes; secondly, how do these chemokines contribute to the local immune responses 
that is a feature of E7 transgenic skin. 
 
We demonstrated that the presence of E7-induced epithelial skin hyperplasia can 
also alter the expression profile of skin chemokines. Importantly, disruption of the E7-Rb 
interaction and epithelial hyperplasia in our study resulted in a reduction in CXCL9 and 
CXCL10 production within the skin. A change in skin chemokines is also seen in several 
other skin disorders and epithelial proliferation associated with wound healing (Gillitzer and 
Goebeler, 2001). For instance, CXCL9 and CXCL10, induced by wounding, facilitates 
epithelial repair through production of growth factors (Yates et al., 2009) and assists in 
preventing infection by promoting pathogen specific immune responses (Thapa and Carr, 
2008). CXCL9/ and CXCL10 can be induced in damaged skin from myeloid cells and 
activated keratinocytes. This attracts CXCR3+ immunocytes as a feature of many 
inflammatory skin disorders (Flier et al., 2001). Similarly, epithelial hyperproliferation, 
induced by deletion of the Mi-2β chromatin remodeler, results in CXCL9 and CXCL10 
chemokine production in skin, and subsequently recruit both effector and regulatory CD4+ T 
cell populations (Kashiwagi et al., 2017). Moreover, CXCR3+ CD4 and CD8 T cells were 
found to be important in enhancing epidermal proliferation in a chemical skin tumorigenesis 
model (Winkler et al., 2011). The effect of hyperplasia on chemokine recruitment of immune 
cells can also be observed in murine hyperplastic cervix (mucosal) induced by either 
transgenic expression of HPV16 E7 or by treatment with estradiol, another commonly 
associated carcinogen for cervical oncogenesis. Genes associated with immune trafficking 
(Cxcl13, Ccl3, Cxcr2) and inflammatory responses (IL-1, TNF, Irf1) were the top up-
regulated categories in both models of hyperplastic cervix (Cortes-Malagon et al., 2013). 
Whether there is an additive effect of the different causes of hyperplasia on immune cell 
trafficking and immune response was not explored but this effect is likely to be an important 
aspect for cervical disease progression. In support of this, neoplastic progression could be 
delayed when non-antigen specific inflammation was reduced by depleting CD4+ T cells 
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(Daniel et al., 2003) in a different HPVE7-induced epithelial hyperplasia mouse model 
(Arbeit et al., 1994). Up-regulation of CXCR2 and its ligands CXCL1, 2, 3 and 5 in K14.E7 
skin (Figure 2.2b) may contribute to increased keratinocyte proliferation as CXCR2 deficient 
animals showed a delayed wound healing process in terms of epithelialization and 
neovascularization (Devalaraja et al., 2000). Together, these findings support the idea that 
epithelial proliferation is the likely driver of elevated chemokine production and the latter is 
further required for progression of the disease. 
 
Although expression of CXCL9 and CXCL10 was dramatically increased in K14.E7 
skin, antagonizing CXCR3 did not change the outcome for K14E7 skin grafts on 
immunocompetent recipients. However, when local immunosuppression was removed by 
utilizing lymphocyte-deficient K14E7 grafts, these grafts were promptly rejected (defined as 
50% of graft shrinkage) in a CXCR3 dependent manner. However, graft rejection was then 
prevented by blocking CXCR3 interactions, suggesting that CXCR3+ T cells function as 
effector cells responsible for graft rejection in these circumstances. But how does this 
infiltrating CXCR3+ effector population fail to reject K14E7 skin grafts on immunocompetent 
recipients? We hypothesise that insufficient CXCR3+ effector cells are recruited to overcome 
local suppressive mechanisms and/or that the infiltrating population undergoes 
programming toward a phenotype ineffective for graft rejection. While CXCR3+ T cells are 
clearly effector cells in our model, they represent only a small subset of the T cells within 
the skin, suggesting that other chemokines may be involved in epithelial hyperplasia-
induced T cell recruitment. Recently, chemokine CXCL14 has been shown to be down-
regulated in a HPV16E7-dependent manner and impacts on anti-tumour immune response. 
Restoration of Cxcl14 expression in HPV-positive mouse oropharyngeal carcinoma cells 
enables the recruitment of NK, CD4+ and CD8+ T cells to tumour draining lymph node 
(Cicchini et al., 2016). Our previous studies have shown that CCR6+ CD4 T cells can be 
recruited via CCL20 to the hyperplastic K14E7 skin (Choyce et al., 2013). CCR6 regulates 
the migration of regulatory T cells (Yamazaki et al., 2008) but depletion of Foxp3+ regulatory 
T cells from either K14.E7 skin graft donor or graft recipients failed to reject K14.E7 skin 
(Mattarollo et al., 2011). In this study, the majority of CXCR3 expression was observed on 
TCRβ+CD4-CD8- T cells (CXCR3+CD4+ and CXCR3+CD8+ T cells comprised, 2.2% and 
0.6%, of total T cells respectively, while the total population of CXCR3+ T cell is 7.5%). This 
unusual CD4-CD8- subset of αβT cells can represent NKT cells, conventional T cells that 
have downregulated CD8 expression to form pro-inflammatory effector cells or alternatively, 
a population of regulatory cells (Brandt et al., 2017; Godfrey et al., 2004; Zhang et al., 2001). 
Chapter 2                                                                                   Kuo, Paula Ting-Yu, 2018 
    34 
 
The presence of a regulatory T cell population in K14.E7 skin, most likely NKT cells, prevents 
rejection of E7 transgenic skin by immunocompetent graft recipients although the chemokine 
attracting NKT cells to K14E7 skin remains unknown (Mattarollo et al., 2010a). Although no 
differential expression of CXCR3 was observed in non-transgenic, K14.E7 and 
K14.E7xRbL/L, this double negative T cell population could also potentially contribute to 
skin immunity in a MHC-independent manner (Tikhonova et al., 2012; Van Laethem et al., 
2007).  
 
Ideally, immunotherapeutic intervention targeting effector immune cell recruitment 
should induce more efficient immune responses to combat cancers. As chronic IFNγ 
stimulation has profound impact on i) CXCL9 and CXCL10 chemokine expression/signalling 
and ii) the fate of K14.E7 skin grafts, one possible strategy may be to increase the infiltration 
of CXCR3+ T cells to HPV-infected lesions and overcome the local suppressive 
environment.  
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2.7 Materials and Methods 
Animals 
Mice were maintained in Translational Research Institute Biological Research Facility under 
specific pathogen free conditions. Female mice were used at 8-12wk of age. C57BL/6, 
K14.E7 (Herber et al., 1996), Rag-/- and B6.SJL.Ptprca mice were obtained from Animal 
Resources Centre (Perth, Australia). IFNγ-/- and IFNγR-/- mice were purchased from The 
Jackson Laboratory (Bar Harbor, ME). Heterozygous RbL/L transgenic mice (Isaac et al., 
2006) were obtained from Dr. Fred Dick. Homozygous RbL/L mice were generated by 
backcrossing C57BL/6 for 10 generations. K14.E7xIFNγ-/-, K14.E7xIFNγR-/-, K14.E7xRag-/- 
and K14.E7xRbL/L mice were generated by mating heterozygous K14.E7 with homozygous 
IFNγ-/-, Rag-/- and RbL/L, respectively. All procedures were approved by the University of 
Queensland Animal Ethics Committee (UQDI/367/13/NHMRC and UQDI/452/16).  
 
FACS and Antibodies  
FACS analysis were undertaken as previously described (Mattarollo et al., 2010a). Foxp3 
Fix/Perm Concentrate and Diluent kit was used for intracellular staining (eBioscience, San 
Diego, USA). CXCL9 and CXCL10 were stained intracellularly with unconjugated goat anti-
mouse polyclonal Ab (R&D, MN, USA) followed by PE-conjugated secondary donkey anti-
goat IgG H&L Ab (Abcam, Cambridge, UK). Anti-mouse monoclonal Abs to CD45.2 (104), 
CD45.1 (30-F11), CD8α (53-6.7), TCRβ (H57-597), CD11b (M1/70), EpCAM (G8.8), CD19 
(6D5), MHCII (I-A/I-E) (M5/114.15.2), IFNγ (XMG1.2), CXCR3 (CXCR3-173), CXCR3 
(Met1-Leu367), CD3 (145-2C11), CD4 (GK1.5), CD11c (HL3) and corresponding isotype 
controls were purchased from Biolegend (San Diego, USA), eBioscience (San Diego, USA), 
BD Bioscience (San Jose, USA) and R&D (MN, USA).  
 
RNA extraction, reverse transcription and qPCR 
RNA Extraction was performed as described (Zhussupbekova et al., 2016). For each 
reverse transcription, 1 μg of extracted RNA was processed using a SuperScriptIII kit (Life 
technology, MA, USA). Primers sequences can be found in Table S2. qPCR was carried out 
on Applied Biosystems™ QuantStudio™ 6 Flex Real-Time PCR System.  
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Sequencing and analysis, GSEA and gene ontology analysis 
RNA sequencing and raw data processing were done as previously described 
(Zhussupbekova et al., 2016). Detailed methods for GSEA and gene ontology analysis can 
be found in the supplementary materials and methods.  
 
Skin Grafting and Reagents 
Grafting was done as previously described (Choyce et al., 2013). Animals were given 
CXCR3 antagonist-AMG487 (Tocris, No. 3387, Bristol, UK) 3 µg/g body weight in DMSO, 
or DMSO alone, subcutaneously. E7 peptide (RAHYNIVTF) was synthesized by Auspep Pty 
Ltd, (Melbourne, Australia), with purity >80%. 
 
Transwell migration assay  
Splenocytes were activated (supplementary methods), and 5 x 105 activated cells in 100 µl 
were seeded into a 5 µm pore trans-well insert (Corning, No. 3421, NY, USA). Supernatants 
from in vitro skin cultures (supplementary methods) were diluted with RPMI in 1:2 ratio, with 
a final volume of 750 µl. As controls, recombinant CXCL9 (250-18, Peprotech, NJ, USA), 
CXCL10 (250-16, Peprotech, NJ, USA), neutralizing antibodies for CXCL9 (AF-492-SP, 
R&D, MN, USA), CXCL10 (AF-466-SP, R&D, MN, USA) or goat IgG isotype control (AB-
108-C, R&D, MN, USA) were added to the bottom well of the transwell culture. Cells were 
incubated at 37°C for 60 minutes and the cells in the bottom wells were collected for FACS 
analysis.  
 
Statistical analysis 
Prism 7 (GraphPad Software, La Jolla, CA) software was used for statistical analysis and to 
prepare the plots. Unless otherwise stated, all analyses were done using one-way ANOVA, 
with Bonferroni’s multiple comparison test. Unpaired Student’s t-test and two-way ANOVA 
were used in Figure 2.6e and Figure 2.6f and j, respectively. All plots show mean value with 
SEM. Result significance was shown, where *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001.  
 
Other methods can be found in Supplementary Method section.  
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Figure 2.1. Effect of E7 expression on local immune responses is minimal in the 
absence of E7 induced epithelial proliferation 
Skin from K14.E7 transgenic was compared with K14.E7xRbL/L and C57BL/6 mice. (a) 
Expression of E7 mRNA relative to an internal control, Hprt. n>3 (b-f) FACS analysis of skin 
infiltrating immune cell populations. (b) live CD45+ cells,; (c) epidermal and dermal antigen 
presenting cell populations- EpCAM+CD11b+ (LC) and EpCAM- CD11b+ (CD11b+ DC) as a 
percentage of CD11c+MHCII+ CD45+ cells; (d) CD11b+ non-DCs (as a percentage of CD3Ɛ-
CD11c- CD45+ cells); (e) CD4 and CD8 T cells under CD3Ɛ+ gate; (f) MHCII+CD45- cells. 
Error bars showing mean+/-SEM of n>3.  
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Figure 2.2. Overexpression of mRNA for chemokine receptors and ligands in E7 
transgenic skin 
(a) Pathway analysis of 482 genes differentially displayed in association with hyperplastic 
skin. Bars, top 10 pathways ranked by -log10 of B-H P-value; dots, number of genes in a 
particular gene ontology group. (b) Heat map of chemokine genes expression in C57BL/6, 
K14.E7 and K14.E7xRbL/L skin. (c) GSEA of CXCR3 pathway signature to the mRNA 
profile of K14.E7 vs. K14.E7xRbL/L and K14.E7 vs. C57BL/6. Black and grey dots, subset 
in the leading edge of the gene set, where 25/40 and 23/40 genes were identified, 
respectively.  
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Figure 2.3. CXCR3 enriched on CD4 T cells in K14.E7 but not K14.E7xRbL/L skin 
CXCR3 expression on CD4+ and CD8+ T cells in skin and spleen. (a and b) Representative 
flow cytometry plots pre-gated on live CD45+TCRβ+ cells. a, skin; b, spleen. (c and d) 
Quantitative results from skin and spleen of 3-5 mice. (e) Representative plots showing 
expression of activation markers by CXCR3+ and CXCR3- CD4 T cells from lymph nodes.  
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Figure 2.4. CXCL9/10 expression in skin is mostly by epidermal CD45- cells  
(a) Expression of Cxcl9/10, normalized with Hprt, relative to C57BL/6, in skin and spleen. 
(b) Intracellular CXCL9/10 were assessed for live cells from epidermis and dermis of K14.E7 
and compared with K14.E7xRbL/L and C57BL/6 mice. (d) Expression of CXCL9/10 on 
CD45-, DCs (CD11c+MHCII+) and T cells (TCRβ+) in K14.E7 epidermis. (c and e) 
Quantitative data showing mean percentage and ΔMFI of (b) and (d), respectively. ΔMFI 
calculated by subtracting signal MFI from isotype control MFI. (a-e) Error bars showing 
mean+/-SEM with n>3 of each sample. (f and g) Immunofluorescent staining of CXCL9/10 
(red) within K14.E7 skin. Blue, DAPI; green, MHCII. Scale bar= 200 µm in (f) 100 µm in (g).  
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Figure 2.5. CXCR3+ T cells migrate to hyperplastic skin environment in vitro and in 
vivo 1 
(a-c) T cell migration assay. 0mM, medium control; +CXCL9/10, 50nM CXCL9; 10nM 
CXCL10; nAb2, neutralizing antibody to CXCL9/10 at 200 ng/ml. Isotype Ab was included in 
K14.E7 supernatant. (c) MFI of surface CXCR3 on migrated T cells with. All compared to 
+CXCL9/10. (d-f) K14.E7 skin grafts were placed onto C57BL/6 (CD45.2) recipient. On day 
21, 5*106 activated B6.SJL.Ptprca (CD45.1) splenocytes were transferred intravenously. 
                                            
1 See Chapter 5 section 2 for full optimisation process of induction of CXCR3 expression on enriched T cells  
2 Procedures of establishing the use of neutralising antibody concentration is outlined in Chapter 5 section 3 
and 4.  
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CXCR3 antagonist-AMG487 or vehicle control was injected subcutaneously for four days. 
On day 25, skin grafts were excised and lymph node and spleen were harvested for FACS 
analysis. (e) Number of CD45.1/ CD45.2 cells found in grafts on day 25. (f) Percentage of 
TCRβ+CD45.1 cells found in different tissues. (d-f) Pooled result from two-independent 
experiments. All error bars showing mean+/-SEM with n>3. 
Chapter 2                                                                                   Kuo, Paula Ting-Yu, 2018 
    45 
 
 
Figure 2.6. CXCR3+ T cells influence on graft rejection  
(a) CXCL9/10 expression level in epidermis and dermis from K14.E7xRag-/- mouse 
expressed as percentage compared to K14.E7. Representative plot showed from n>3. (b-f) 
Skin graft recipients received E7-peptide (50µg) subcutaneously 7 days before grafting. 
Recipients were grafted with K14.E7 (left) and K14.E7xRag-/- (right) ear skin and treated 
with either vehicle control or AMG487 daily. N>5 per treatment group. All error bars showing 
mean+/-SEM. (c) CXCR3+ T lymphocytes (TCRβ+CD45.1) in K14.E7 skin grafts treated with 
vehicle control or AMG487. Cell numbers were normalized by skin graft size (per cm2). 
Unpaired student t-test with *p<0.05 performed. (d) Percentage of CXCR3+CD4+ and 
CXCR3+CD8+ cells in K14.E7 skin graft treated with vehicle control. (e) Skin grafts on day 
27, scale bar= 10 mm. (f) Percentage of graft survival.  
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Supplementary Methods 
Histology sample preparation 
For hematoxylin and eosin staining, ear skin was harvested and fixed in 4% 
paraformaldehyde solution overnight. Tissues were embedded in paraffin, sectioned and 
stained following standard protocol. For immunofluorescence staining, tissues were 
embedded in OCT and cryosectioned at 7 mm.  
 
Isolation of cells from ear skin, lymph node and spleen 
Ear skin was split into dorsal and ventral parts and incubated with 2.5 μg/μl Dispase II 
(Roche, Basel, Switzerland) for 1 hour at 37°C. Epidermis and dermis were separated with 
closed forceps and homogenized. Skin was further digested with 1 μg/μl, of collagenase D 
(Roche, Basel, Switzerland) and 0.2 μg/μl of DNase, (Roche, Basel, Switzerland) for 1hour 
at 37°C. Lymph node and spleen were mashed with syringe plunger and passed through 
0.7 μm filter (BD Falcon, San Jose, USA). For each spleen, red blood cells were lysed with 
1 ml of ACK buffer (0.15 M NH4Cl, 1 mM KHCO3, and 0.1 mM Na2EDTA) for 30 seconds at 
room temperature and the reaction was stopped by adding 10 ml of FACS buffer (2 mM 
EDTA, 2% FCS in PBS).  
 
Immunofluorescence staining 
Skin tissue was embedded in OCT and cryosectioned at 7 µm onto Superfrost™ Plus slides 
(4951PLUS4, ThermoFisher, MA, USA). All procedures were done at room temperature. 
Samples were fixed in acetone for 5 minutes and blocked with 10% donkey serum in TBS 
buffer for 1 hour. Primary antibodies against CXCL9 and CXCL10 were diluted with TBS in 
1:40 ratio and incubated with samples for 1 hour followed by 30 minutes of secondary Ab 
(Donkey Anti-Goat, Alexa Fluor 488, Abcam, Cambridge, UK) incubation. Samples were 
blocked again with 10% goat serum in TBS buffer for 1 hour. Primary Ab against MHCII 
(107628, Biolegend, San Diego, USA, ) was diluted with TBS in 1:200 ratio and incubated 
with samples for 1 hour followed by 30 minutes of secondary Ab (Goat Anti-Rat IgG (H+L), 
FITC) incubation. All secondary antibodies were prepared in TBS in 1:200 ratio. 
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Skin Explant Culture  
Skin explant culture was performed as previously described (Gosmann et al., 2014b). 
Briefly, ear skin was split into dorsal and ventral part and spread flat in 24-well plate with 1 
ml of complete RPMI. Culture medium was changed after 1 hour and changed again after 
another 2 hours. Skin was further cultured with 1 ml medium for 20-24 hours and supernatant 
was collected.  
 
Sequencing and analysis, Gene Set Enrichment Analysis (GSEA) and gene ontology 
analysis 
Standard analysis procedure was performed following previous protocol (Subramanian et 
al., 2005).  
The gene signatures of K14.E7 (n=3) and K14.E7 x RbL/L (n=3) were curated from the 
RNAseq data processed as mentioned above. Genes were pre-ranked based on the 
significance of differential expression to C57BL/6 (n=3) and the top ~300 genes from the 
pre-ranked gene list were set as signature. Stage 1, 2 and 3 CIN patient RNA expression 
profile was extracted from de Boon et al., 2015 GSE643. CXCR3 pathway signature was 
adopted from PID (version: BioPAX3).  
Candidate genes identified (hyperplastic gene list) were uploaded as input (482 genes) for 
functional annotation using Database for Annotation, Visualization and Integrated Discovery 
(DAVID) 6.8. Fisher exact probability with P<0.05 to determine significantly enriched gene 
set (Huang da et al., 2009). 
 
T cells enrichment assay  
Single cell suspension from spleen was incubated (1 x 108 cells/reaction) with 5% rat serum 
and biotin-labelled antibodies- CD19 (clone 6D5, Biolegend, San Diego, USA), CD11b 
(clone M1/70, Biolegend, San Diego, USA) and CD11c (clone N418, Biolegend, San Diego, 
USA) in 1:200 dilution in 1 ml of FACS buffer for 15 minutes at room temperature. 
Strepavidin beads (EasySep™ Streptavidin RapidSpheres™ 50001, STEMCELL 
technologies, Canada) were mixed thoroughly and 75 μl was added into each 1ml reaction 
and let sit at room temperature for 2 minutes. FACS buffer was added to top up the volume 
to 2.5 ml/reaction before placed in the EasySep™ Magnet (STEMCELL technologies, 
Canada). Enriched T cells were poured out from the tube and counted for further use.  
 
Chapter 2                                                                                   Kuo, Paula Ting-Yu, 2018 
    48 
 
T cell in vitro activation  
To achieve optimal CXCR3 expression, T cells were stimulated with immobilized antibodies 
- αCD3 (3 µg/ml, clone 17A2, eBioscience, San Diego, USA) and αCD28 (3 µg/ml, clone 
37.51, eBioscience, San Diego, USA) in 1M Tris-HCL (pH9.4) overnight at 4°C. Enriched T 
cells were seeded at a density of 2 x 106 cells/well in complete RPMI following with 
centrifugation of the whole plate. Cells were cultured at 37°C for 2 days then washed with 
PBS before re-plating in complete RPMI without activating antibodies for 1 day. 
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Supplementary Figures  
 
Figure S2.1. 
a) Histological analysis of ear skin sections with haematoxylin and eosin (H&E) staining from 
indicated animals. Scale bar = 500 μm. b) FACS analysis of CD11b+ non-DCs, DCs, CD4+ 
and CD8+ T cells in spleens of indicated animal strains.  
Chapter 2                                                                                   Kuo, Paula Ting-Yu, 2018 
    50 
 
 
Figure S2.2. 
(a-d) GSEA analysis of K14.E7 skin gene signature to CIN stages. Top 300 up-regulated 
genes in K14.E7 vs. C57BL/6 were identified as K14.E7 skin signature and projected onto 
ranked differential expression profiles. (a) CIN3 vs. CIN1/CIN2, (b) CIN2 vs. CIN1, (c) CIN3 
vs. CIN and (d) Cancer vs. CIN3. Black lines indicate leading edge subset of the gene set. 
(e) Venn diagram of differentially expressed genes in indicated comparison. 
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Figure S2.3. 
(a) CXCL9 and CXCL10 expression level on CD45- cells in skin of K14.E7 and 
K14.E7xIFNγKO. Black lines, signal staining; grey lines, isotype control. (b) Quantitative 
data of (a) showing ΔMFI, calculated by subtracting signal MFI from isotype control MFI. (c) 
Log2RPKM of Cxcl9 and Cxcl10 expression level from whole skin RNA sequencing of 
C57BL/6, K14.E7, K14.E7xIFNgRKO and K14.E7xRbΔL/ΔL. Results showing one experiment 
with three biological replicates. Two independent experiments were done.   
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Figure S2.4. 
CXCL9 and CXCL10 expression level on DCs (CD11c+MHCII+) in the epidermis of C57BL/6 
and K14.E7 skin. Black lines, isotype control; grey lines, signal staining. Quantitative data 
showing ΔMFI, calculated by subtracting signal MFI from isotype control MFI. Results 
showing one experiment with three biological replicates. Two independent experiments 
were done.   
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Supplementary Tables  
Table S2.1. ROAST and CAMERA analysis on CXCR3 pathway 
ROAST (rotation gene set testing) Testing whether genes are differentially expressed in gene sets 
K14.E7 vs C57BL/6 NGenes PropDown PropUp 
Direction  
(in K14.E7) P-value FDR 
PID_CXCR3_Pathway 43 0.2325581 0.5813953 Up 0.001 0.001 
K14.E7 vs K14.E7 x Rb∆L/∆L 
     
  
PID_CXCR3_Pathway 43 0.1860465 0.627907 Up 0.001 0.001 
 
CAMERA (competitive gene set testing) 
Testing whether the genes in the set are highly ranked in terms of differential 
expression relative to genes not in the set 
K14.E7 vs C57BL/6 NGenes 
Direction  
(in K14.E7) P-value 
PID_CXCR3_Pathway 43 Up 0.09959264 
K14.E7 vs K14.E7 x Rb∆L/∆L   
PID_CXCR3_Pathway 43 Up 0.008101752 
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Table S2.2. Primers sequence 
 
Gene Name Forward primer (5’-3’) Reverse primer (5’-3’) 
Gapdh TGACCACAGTCCATGCCATC GACGGACACATTGGGGGTAG 
Hprt AGCGTCGTGATTAGCGATGA CTCGAGCAAGTCTTTCAGTCCT 
Hpv16e7 GACAAGCAGAACCGGACAGA TTTCTGGGAACAGATGGGGC 
Cxcl9 TGTGGAGTTCGAGGAACCCT TGCCTCGGCTGGTGCTG 
Cxcl10 AGTGCTGCCGTCATTTTCTG ATTCTCACTGGCCCGTCAT 
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Additional data not described in article 1 
Following the identification of that CXCR3+ T cells are required for K14.E7xRagKO skin graft 
rejection, we investigated whether CXCR3+ T cells are sufficient to enable K14.E7 skin graft 
clearance. To test this hypothesis, we grafted C57BL/6 skin alongside with K14.E7 skin on 
non-transgenic immunocompetent recipients. E7TCR269 mice were immunised with GF001 
peptide and T cells were activated seven days after immunisation following protocol outlined 
in section 5.2 of chapter 5. FACS sorted CXCR3+ or CXCR3- T cells (200,000 per recipient) 
were transferred intravenously on day 14 (0 day post injection, DPI) and graft size was 
monitored until day 49 (35 DPI) (Figure 2.7a)3. No significant difference was observed 
between CXCR3+ or CXCR3- T cells receiving groups and no graft showed reduction in size 
at the end point of the experiment (Figure 2.7b). However, as shown in Figure 2.6, without 
this population, E7-expressing skin graft rejection can be prevented. This result suggests 
that CXCR3+ T cell alone is not sufficient, but is required, to induce K14.E7 skin graft 
rejection. As CXCR3 expression is dynamic, sorted CXCR3 positive or negative cells can 
down-regulate or upregulate this marker, respectively, upon transfer or being influenced by 
the in vivo environment. Potentially, the results showing in Figure 2.7 could be limited by the 
changing dynamics of CXCR3 expression. To circumvent this limitation, CXCR3 positive T 
cells can be obtained from T cell lines that express CXCR3 constitutively and CXCR3 
negative T cells from CXCR3 knockout mice can be utilised. 
  
                                            
3 Detailed process for tracking sorted CXCR3+ and CXCR3- T cells in skin grafts is outlined in Chapter 5 section 
5. 
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a 
 
 
 
b 
 
 
 
 
 
 
 
 
Figure 2.7 CXCR3+ T cells are not sufficient to induce K14.E7 skin graft rejection 
C57BL/6 and K14.E7 ear skin were grafted onto C57BL/6 recipients. Recipients receive 
either 200,000 CXCR3+ or CXCR3- cells intravenously 14 days after grafting (0 DPI) and 
skin graft monitored until day 49 (35 DPI). Each experimental group includes five biological 
replicates. (a) experiment timeline. (b) percentage of graft survival. Graft size on the day of 
injection was set as 100%. Circle, C57BL/6 skin graft; square, K14.E7 skin graft; closed 
symbol, CXCR3- cell-receiving group; open symbol, CXCR3+ cell- receiving group.  
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Chapter 3  
 
 
 
 
 
 
Recruitment of APC to Skin Draining Lymph Node 
from HPV16E7-Expressing Skin Requires E7-Rb 
Interaction
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3.1 Preface 
This chapter covers two aims of the project- aim one and three. I characterized the immune 
responses of K14.E7xRbΔL/ΔL upon immunization, grafted K14.E7xRbΔL/ΔL skin on syngeneic 
immune competent recipients and examined the factors that influence the fate of the 
K14.E7xRbΔL/ΔL skin graft. This chapter is written in manuscript format and will be submitted 
as an original research article.  
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3.2 Article 2 
Original Article  
 
 
Recruitment of APC to Skin Draining Lymph Node from HPV16E7-Expressing Skin 
Requires E7-Rb Interaction 
 
Paula Kuo1, Zewen K. Tuong1, Siok Min Teoh1, Ian H. Frazer1*, Stephen R. Mattarollo1*, 
Graham R. Leggatt1* 
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3.3 Abstract 
“High-risk” human papillomaviruses (HPV) infect keratinocytes of squamous epithelia. The 
HPV16E7 protein induces epithelial hyperplasia by binding Rb family proteins and disrupting 
cell cycle termination. Murine skin expressing HPV16E7 as a transgene from a keratin 14 
promoter (K14.E7) demonstrates epithelial hyperplasia, dysfunctional antigen presenting 
cells, ineffective antigen presentation by keratinocytes, and production of immunoregulatory 
cytokines. Furthermore, grafted K14.E7 skin is not rejected from immunocompetent non-
transgenic recipient animals. To establish the contributions of E7, of E7-Rb interaction and 
of epithelial hyperplasia to altered local skin immunity, K14.E7 skin was compared with skin 
from K14.E7 mice heterozygous for a mutant Rb unable to bind E7 (K14.E7xRbΔL/ΔL mice),  
that have normoplastic epithelium. Previously, we demonstrated that E7-speicfic T cells do 
not accumulate in K14.E7xRbΔL/ΔL skin grafts. Here, we further show that 
K14.E7xRbΔL/ΔL skin, like K14.E7 skin, is not rejected by immunocompetent non-
transgenic animals. There were fewer CD11b+ antigen presenting cells in skin draining 
lymph nodes from animals recipient of K14.E7xRbΔL/ΔL grafts, when compared with 
animals receiving K14.E7 grafts or K5mOVA grafts. Maturation of migratory DCs derived 
from K14.E7xRbΔL/ΔL grafts found in the draining lymph nodes is significantly lower than 
that of K14.E7 grafts. Surprisingly, K14.E7xRbΔL/ΔL keratinocytes, unlike K14.E7 
keratinocytes, are susceptible to E7 directed CTL-mediated lysis in vitro. We conclude that 
E7-Rb interaction and its associated epithelial hyperplasia partially contribute to the 
suppressive local immune responses in area affected by HPV16E7 expression.   
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3.4 Introduction 
Infection of the cervix with high-risk Human Papilloma Virus (HPV) accounts for ~100% of 
cervical cancer. While most high-risk HPV infections can be cleared spontaneously in 
immune competent individuals, 1-2 % of the infected subjects can progress to cervical 
intraepithelial neoplasia (CIN) and persist for decades before developing into cervical cancer 
(Centers for Disease Control and Prevention, 2017). A major risk factor for development of 
cervical premalignancy is immune response gene polymorphism (Leo et al., 2017), 
suggesting that an inadequate immune response is a determinant of development of 
premalignancy, but the basis of an inadequate immune response remains uncertain.  
HPV specifically infects basal layer keratinocytes, and the virus life cycle is linked to 
keratinocyte differentiation (Stubenrauch and Laimins, 1999). Normally, keratinocytes are 
able to presenting antigen to primed T cells (Black et al., 2007; Kim et al., 2009; Zhou et al., 
2011) However, HPV16 E7 transgenic primary keratinocytes are not susceptible to CTL-
mediated lysis by E7-specific T cells in vitro (Leggatt et al., 2002). This defect of endogenous 
antigen presentation could be specific to the E7 antigen, as keratinocytes expressing OVA 
as transgenic antigen are sensitive to cell-mediated lysis by CD8+ OT-1 cells (Kim et al., 
2009; Zhou et al., 2011), in a dendritic cell (DCs) and Langerhans cell-independent manner 
(Kim et al., 2009). In addition to in vitro studies using immortalized or primary keratinocytes, 
a transgenic mouse model expressing HPV16E7 protein controlled by keratin 14 (K14) 
promoter (K14.E7) has been used to study persisting HPV16 gene expression as this model 
harbors the molecular features of CIN3 tissue (Tuong et al., 2018). Multiple local factors 
including suppressive immunity mediated by CD4+CD25+ cells against multiple immunogens 
(Narayan et al., 2009), IFNγ-producing NKT cells (Mattarollo et al., 2010a), impaired antigen 
processing and T cell activation by antigen-presenting cells (APCs) (Chandra et al., 2016) 
are observed in the skin of K14.E7 transgenic mice, and the ear skin of K14.E7 mice is not 
rejected when grafted to immunocompetent recipient mice (Matsumoto et al., 2004)., 
reflecting the failure of clearance of persistent HPV16 infection in human patients.  
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HPV16 E7 protein interacts with multiple proteins including γ-tubulin, p-600, 
Retinoblastoma (Rb) protein family, HDAC, E2F6, p21, and IRF1 (Moody and Laimins, 
2010).The interaction between E7 and Rb disrupts normal cell cycle regulation, leading to 
epithelial hyper-proliferation, one of the major pathological phenotypes of CIN3 patients. 
However, it is unclear whether suppressed local immunity is a result of E7-associated 
hyperplasia or some other consequence of expression of the viral protein. To dissect this 
question, we utilized transgenic mice expressing the E7 protein and with a mutant Rb that 
is functional for cell cycle regulation but cannot bind E7 (K14.E7xRbΔL/ΔL) (Dick et al., 2000). 
Expressing comparable level of E7 transcript, the skin of K14.E7xRbΔL/ΔL mice, whether 
homozygous or heterozygous for the Rb mutation, was found to closely resemble non-
transgenic mouse skin (Choyce et al., 2013; Kuo et al., 2017). To test whether the local 
immune suppression observed in K14.E7 transgenic mouse skin was due to 
hyperproliferation or to some other action of E7 protein, we examined immune function in 
the skin of K14.E7 and K14.E7xRbΔL/ΔL mice. However, K14.E7xRbΔL/ΔL skin grafts were 
not rejected from naïve or E7 primed recipients, and this was associated with reduced 
numbers of CD11b+ DC, as well as the low expression of maturation markers- CD80 and 
CD86 on migratory DC subtypes in the skin draining lymph nodes. More importantly, 
adaptive immune responses to skin-directed antigen in K14.E7xRbΔL/ΔL mice were 
comparable to those in non-transgenic wild-type mice, and K14.E7xRbΔL/ΔL transgenic 
keratinocytes could present endogenous E7-antigen and be recognized by antigen specific 
CD8 T cells in vitro, unlike E7 transgenic keratinocytes. 
  
Chapter 3                                                                                   Kuo, Paula Ting-Yu, 2018 
    63 
 
3.5 Results 
Disruption of E7-Rb interaction in E7 transgenic mice restores peripheral T cell response to 
that of non-transgenic animals  
Mice expressing E7 as a transgene in epithelial cells have altered immune function locally 
in skin. The major effects of E7 in epithelial cells are mediated via binding to the Rb cell 
cycle regulatory protein. To determine whether disruption of E7-Rb interaction impacts on 
the altered immune response in E7 transgenic skin, we first examined induction of peripheral 
CD8 T cell responses, as these are impaired in E7 transgenic animals to multiple 
immunogens (Narayan et al., 2009). K14.E7 mice and K14.E7 x RbΔL/ΔL mice were 
immunised with ovalbumin intradermally, and IFNγ production by CD8 T cells from the 
draining lymph node in response to SIINFEKL was measured six days after immunisation. 
Re-stimulation with SIINFEKL resulted in IFNγ production by +0.11% of K14.E7xRbΔL/ΔL CD8 
T cells and +0.215% of C57BL/6 CD8 T cells compared to unstimulated control, significantly 
more than in K14E7 animals similarly immunised, which only showed a +0.035% increase 
in IFNγ CD8 T cells compare to unstimulated control (Figure 3.1). Thus, adaptive immune 
priming within K14.E7 x RbΔL/ΔL mice do not seem to be affected. 
 
K14.E7xRbΔL/ΔL skin is not rejected from immunocompetent syngeneic recipients  
K14.E7xRbΔL/ΔL mice and non-transgenic mice have similar composition of skin-infiltrating 
lymphocytes (Kuo et al., 2017), and exhibit similar local immunity (Figure 3.1), as well as a 
similar transcriptomic profile to a non-transgenic mouse skin (Kuo et al., 2017; 
Zhussupbekova et al., 2016). We therefore hypothesized that E7-expressing skin lacking 
hyperplasia might be susceptible to immune mediated rejection. To test this hypothesis, we 
grafted K14.E7xRbΔL/ΔL skin onto syngeneic non-transgenic mice. As controls, we grafted 
hyperplastic NKT cell deficient Jα18KO x E7 skin, which is susceptible to rejection, 
(Mattarollo et al., 2010a) and K14.E7 skin, which is not. Jα18KO x E7 skin grafts showed 
rejection, defined as more than 50% shrinkage within 42 days (Figure 3.2a and b). However, 
both K14.E7xRbΔL/ΔL and RbΔL/ΔL skin grafts showed no evidence of rejection (Figure 3.2a 
and b).  
 
As there is no chemokine mediated accumulation of regulatory T cells in K14.E7xRbΔL/ΔL 
skin, as observed in K14.E7 skin, a different mechanism must prevent E7 specific priming 
or effector functions where E7 transgenic grafts are not associated with hyperplasia.  
Passive transfer of sufficient E7-specific cytotoxic CD8 T cells enabled rejection of E7- 
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expressing skin grafts following immunization (Matsumoto et al., 2004). We therefore tested 
whether a similarthis approach would lead to rejection of K14.E7xRbΔL/ΔL skin grafts. K14.E7 
and K14.E7xRbΔL/ΔL skin together were grafted on to the same E7TCR269 
recipientrecipients that have an expanded E7-specific CD8 T cell repertoire (Narayan et al., 
2009) (Supplementary Figure 1),, and to non-transgenic recipients,  with or without prior 
immunization with an H-2 Db restricted peptide of E7 (GF001) (Figure 2c). Consistent with 
our previous findings, K14.E7 grafts showed ~40% reduction in size on immunized 
E7TCR269 recipients (Figure 2d and e). In contrast, K14.E7xRbΔL/ΔL grafts showed no 
reduction in size on either C57BL/6 or E7TCR269 recipient mice. These data demonstrate 
that failure of E7 transgenic skin grafts to prime an E7-specific response is not the sole 
reason for failure of rejection of K14.E7xRbΔL/ΔL grafts.  As E7-expression levels are similar  
in K14.E7 and K14.E7xRbΔL/ΔL skin (Kuo et al., 2017), it is unlikely that the expression level 
of the antigen influenced the fate of K14.E7xRbΔL/ΔL skin grafts. Thus, we hypothesized three 
possibilities of why the K14.E7xRbΔL/ΔL skinThus, these grafts are tolerated- i) 
K14.E7xRbΔL/ΔL skin graft alone may not initiate sufficient skin antigen presenting cell 
migration and activation in the draining lymph nodes to prime T cells; ii) K14.E7xRbΔL/ΔL skin 
graftseither fail to attract effector cells,  consistent with their lower expression of T cell 
attracting chemokines (Kuo et al. 2017); iii)), or E7 transgenic KC fail to present antigen 
effectively in the absence of the local inflammatory signals (IL-1, IL-17) that are a feature 
of K14.E7 skin  (Tuong et al., 2018).   
 
Limited presence of graft-derived dendritic cells in the draining lymph node was observed 
upon K14.E7xRbΔL/ΔL skin grafting  
We next investigated why E7-expressing skin, without the altered local immunity associated 
with hyperplasia (K14.E7xRbΔL/ΔL), was not rejected when grafted onto syngeneic 
background recipients. There are three critical steps involved in allogenic skin graft rejection. 
Firstly, antigen specific T cells are generated in the draining lymph node following migration 
of antigen-loaded dendritic cells from the skin. Secondly, primed T cells egress out of the 
lymph node are attracted to or retained in the targeted tissue. Lastly, effector T cells 
recognise the antigen and induce CTL-mediated killing.  
 
We first determined whether K14.E7xRbΔL/ΔL skin-derived dendritic cells could be found in 
the draining lymph node. K14.E7xRbΔL/ΔL skin was transplanted onto congenic (CD45.1) 
recipients and draining lymph nodes (axillary and inguinal) from both grafted and non-grafted 
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flanks were harvested. To validate the separation of CD45.1 from CD45.2 lymphocytes, 
naïve lymph nodes from C57BL/6, B6.SJL.Ptprca, and 1:1 mixture of the two were stained 
with CD45.1 antibody (Figure S3.1a). Figure S3.1b shows the same gating strategy as 
Figure S3.1a. Lymph nodes were harvested and analysed 11 days post-grafting to minimise 
the effect caused by the surgical procedure. Differences in relative and absolute numbers 
of specific APC population in draining lymph nodes at this time point might reflect differences 
in migration, proliferation, maturation or turnover of skin-derived DCs. To establish the 
impact of the skin grafting procedure on APC migration, C57BL/6 skin was grafted as 
negative control, and to establish the profile of APC migration associated with skin graft 
rejection, skin expressing membrane-bound OVA driven by keratin 5 promoter (K5mOVA) 
was grafted (Azukizawa et al., 2003; Hadis et al., 2010) (Figure 3.3a). Percentage and total 
numbers of recipient-derived CD11c+ cells between the grafted and non-grafted sides were 
similar in recipients bearing different types of skin grafts (Figure S3.2). Higher absolute 
number of graft-donor derived CD11c+ cells were found in the graft draining lymph node 
than in the contralateral node (Figure 3.3b). However, percentage of graft-derived CD11c+ 
cells was significantly less in lymph nodes receiving C57BL/6, K14.E7xRbΔL/ΔL and RbΔL/ΔL 
grafts than those bearing K5mOVA or K14.E7 skin grafts (Figure S3.1b and c). Significantly 
reduced numbers of graft-derived CD11c+ cells was found in the draining lymph nodes of 
C57Bl/6, K14.E7xRbΔL/ΔL and RbΔL/ΔL bearing recipients, when compared with K5mOVA 
recipients. K14.E7 skin grafts induced similar percentages of CD11c+ cell in the draining 
lymph node to K5mOVA graft (Figure S3.1b), Graft-derived cells were further analysed 
based on CD11c and MHCII expression level to differentiate migratory DC (CD11c+ MCHIIhi 
migDC) from resident DC (CD11c+ MCHIIint ResDC). Significant amount of MigDC, but not 
ResDC, was found in the draining lymph nodes (Figure 3.3c), demonstrating the migratory 
property of cells were of skin graft origin. The number of migratory DC (CD11c+ MCHIIhi) 
from K14.E7 grafts was similar to K5mOVA skin graft (Figure 3.3 c and d). The total amount 
of MigDC from K14.E7xRbΔL/ΔL skin graft was significantly lower than the rejection control, 
K5mOVA, and the E7-expressing hyperplastic skin, K14.E7 (Figure 3.3d). Increased 
numbers of CD11b+ migratory DCs but not CD103+ DC or LC were found in the lymph nodes 
of K5mOVA and K14.E7 grafted animals (Figure 3.3f). Interestingly, significantly less K14.E7 
skin-derived CD11b+ migratory DC was found when compared to K5mOVA skin, but the 
number was still significantly higher than that derived from C57BL/6, K14.E7xRbΔL/ΔL and 
RbΔL/ΔL skin graft.  
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Next, we further examined the maturation state of different subtypes of DC in the draining 
lymph nodes derived from either K14.E7 or K14.E7xRbΔL/ΔL skin, based on the expression 
of CD80 and CD86. Analysed at the same time point, the percentage and MFI of CD80 and 
CD86 on migratory DC, including CD103+ and CD11b+ migratory DC, are significantly higher 
on cells derived from the K14.E7 skin graft (Figure 3.3g). No significant difference was 
observed in resident DC subtypes. This suggests that K14.E7xRbΔL/ΔL skin graft-derived DC 
not only cannot sufficiently migrate to the draining lymph node, but also that the migrated 
DC are not mature DC.  skin grafts.Together, these results suggest that grafting of 
K14.E7xRbΔL/ΔL skin induces lesser numbers of skin-derived DCs to migrate to the draining 
lymph node when compared to grafts of K14.E7 or K5mOVA, skin and the number of 
K14.E7xRbΔL/ΔL skin-DCs is similar to that from non-transgenic skin grafts, which potentially 
could explain the failure of rejection of K14.E7xRbΔL/ΔL skin grafts.  
  
Keratinocytes with disrupted E7-Rb interaction engage with antigen-specific CD8 T cells and 
enable CTL-mediated lysis  
Previously, we have demonstrated that activated antigen-specific CD8 T cells can enter both 
hyperplastic (K14.E7) and normoplastic (K14.E7xRbΔL/ΔL) E7-expressing epidermis 
(Jazayeri et al., 2017). However, only a very low number of antigen-specific T cells can enter 
or be retained in the K14.E7xRbΔL/ΔL epidermis. The final step of allograft rejection is the 
engagement of effector T cells and antigen expressing keratinocytes, followed by CTL-
mediated lysis. An in vitro approach was therefore utilised to assess whether keratinocytes 
of K14.E7xRbΔL/ΔL epidermis are susceptible to CTL-mediated lysis when sufficient antigen-
specific effector cells are present. FACS sorted-keratinocytes of the epidermis were 
exposed to H-2 Db restricted peptide of E7 (GF001) (Figure 3.4a), OVA (SIINFEKL) (Figure 
S3.4a) or not so exposed (Figure 3.4b), and were co-cultured with E7 peptide-specific 
effector T cells, or with SIINFEKL-specific OT-1 cells (Figure S3.4b-d) as controls. 
Consistent with previous findings, keratinocytes isolated from K14.E7 epithelium were 
susceptible to CTL-mediated lysis only when exposed to exogenous peptide antigen (Zhou 
et al., 2011) (Figure 3.4a and 3.4b). In contrast, keratinocytes of the K14.E7xRbΔL/ΔL skin 
were susceptible to lysis without exogenous peptide provision, likely due to endogenous 
antigen presentation (Figure 3.4a and 3.4b). Target cell maximum release and spontaneous 
release of LDH are plotted in Figure S3.3. These results suggest that E7-Rb interaction or 
E7-induced cell proliferation interferes with effective MHC class I antigen presentation, and 
that disruption of E7-Rb interaction or of the resulting cellular proliferation can restore the 
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susceptibility of E7-expressing keratinocytes to cytotoxic T cell killing. Thus, E7 transgenic 
skin with no E7-Rb interaction demonstrates normal peripheral immunity but antigen 
expressing keratinocytes are not eliminated in vivo, though susceptible to lysis in vitro. This 
may reflect failure of skin-derived APC in the draining lymph node to prime or promote 
migration of effector T cells to the E7 transgenic skin.  
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3.6 Discussion 
In this manuscript, we demonstrate that while E7-transgenic keratinocytes from normally 
proliferative epithelium are susceptible to immune lysis in vitro, unlike E7 transgenic 
keratinocytes from hyperproliferative epithelium, neither grafting induced nor vaccine 
induced immune responses can eliminate E7 transgenic grafts of normally proliferative 
epithelium. This was associated with lesser accumulation of CD11b+ APC from the skin graft 
in the skin draining lymph nodes. The immune landscape of the tumour microenvironment 
is altered in association with enhanced cell proliferation. Suppressed local immunity has 
been extensively studied by our laboratory and others in hyperproliferative epithelium 
associated with expression of the HPV16E7 protein (Bergot et al., 2014; Chandra et al., 
2016; Choyce et al., 2013; Gosmann et al., 2014b; Matsumoto et al., 2004; Mattarollo et al., 
2010a). One of the mechanisms contributing to the suppressive immunity is that a different 
profile of cytokines and chemokines is generated, resulting in an altered balance in the 
hyperproliferative microenvironment that often favours the regulatory/inhibitory response 
(Kuo et al., 2017). Thus, targeting the hyperproliferation might rebalance the immune 
response in favour of elimination of HPV infected tissue.  
 
 As transplantation of the hyperproliferative K14.E7 skin results in graft tolerance 
(Matsumoto et al., 2004), we aimed to dissect the role of hyperplastic epithelium plays in 
determining the fate of E7-expressing skin grafts. Rejection of an allogeneic skin transplant 
is typically initiated by the migration of graft-derived DC to the draining lymph node, where 
they activate host T cells (Larsen et al., 1990; Richters et al., 1999). Meanwhile, the skin 
transplant provides allogeneic antigen, which can be processed and presented by the 
recipient’s antigen presenting cells. Together, both sensitizations result in an influx of 
recipient CD4, CD8 T cells and CD11b+ macrophages to the graft and graft rejection 
(Richters et al., 2005). Moreover, rejection of an allogeneic graft relies on the efficient 
presentation of the allogeneic antigen to the recruited cells to elicit antigen specific cytotoxic 
effect (Arnold et al., 1990; Gould and Auchincloss, 1999). Thus, i) T cell priming by antigen 
presenting cells in the lymph node, ii) influx of effector cells to the localized area and iii) 
engagement of cytotoxic T cells to the antigen are three critical aspects that determine the 
outcome of an allogeneic skin transplant.  
 
 Following skin grafting, we identified that the dendritic cells derived from the skin of 
K14.E7xRbΔL/ΔL mice are of lower abundance in the draining lymph node, when compared 
to those derived from non-transgenic skin. Furthermore, the lower number of migratory 
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CD11b+ DC derived from K14.E7xRbΔL/ΔL skin was not due to the thickness of skin graft, as 
both K5mOVA and K14.E7xRbΔL/ΔL skin are normoplastic. Failure of migration of adequate 
numbers of skin derived APC might result in an insufficient amount of primed T cells. The 
limited migration of K14.E7xRbΔL/ΔL skin-derived DC could be due to their immaturity in 
K14.E7xRbΔL/ΔL skin when compared with K.14E7 skin which demonstrates production of 
proinflammatory cytokines including IL-1 and IL-17 which would assist maturation of APCs. 
Antigens delivered though intradermal injection can be drained to the lymph node through 
lymphatic system and taken up by functional lymph node resident dendritic cells (Levin et 
al., 2017), bypassing the migration step of antigen-carrying skin-derived DC from skin to the 
draining lymph node. In this regard, intradermal immunisation is a better assessment for 
peripheral T cell response. We showed effective CD8 T cells response to intradermal OVA 
immunisation in K14.E7xRbΔL/ΔL mice, suggesting a functional peripheral immunity in the 
K14.E7xRbΔL/ΔL as opposed to K14.E7 animals (Malcolm et al., 2003). It is likely that the 
suppressed adaptive immunity in the HPV16E7 transgenic mice is dependent on the 
interaction between E7 and Rb.  
 
Another reason for tolerance of the K14.E7xRbΔL/ΔL skin could be the lack of antigen-
specific effector T cell infiltration to the graft. In contrast to K14.E7xRbΔL/ΔL , the hyperplastic 
K14.E7 skin is able to induce trafficking of both antigen specific and non-specific effector T 
cells to the epidermis (Jazayeri et al., 2017). However, this does not confer graft rejection of 
K14.E7 grafts. It is likely that in the absence of epithelial hyperplasia in K14.E7xRbΔL/ΔL 
epidermis results in insufficient signals produced to induce immunocyte trafficking to the 
local area (Kuo et al., 2017). We hypothesized that if the lack of localised recruitment of T 
cells was to be overcome by provision of sufficient antigen-specific effector T cells, antigen-
bearing keratinocytes from the K14.E7xRbΔL/ΔL skin could be lysed. We utilised in vitro CTL-
mediated lysis assay to supply sufficient antigen-specific effector T cells. In contrast to 
K14.E7 keratinocytes, which are susceptible to lysis only if exogenous peptide is provided, 
keratinocytes from K14.E7xRbΔL/ΔL animals are able to present endogenous antigen and are 
susceptible to CTL-mediated lysis in vitro. This finding is consistent with the observation that 
immunisation-induced immunity is ineffective in rejecting E7-expressing K14.E7xRbΔL/ΔL skin 
as the lack of presentation of antigen by the skin-derived APC in the draining lymph node in 
the K14.E7xRbΔL/ΔL mice fails to induce local inflammatory responses that are necessary for 
activation of effector T cells trafficking to the skin.  
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Recently, a small thiadiazolidinedione molecule binding to pRb through the LxCxE 
motif was identified and it was shown to selectively interfere with HPV16E7-Rb but not 
HPV18E7-Rb interaction (Fera et al., 2012). This small molecule interrupts the E7-Rb 
interaction the same manner as the K14.E7xRbΔL/ΔL does. Moreover, this molecule 
demonstrated effects on cell cycle and reduced TC-1 tumour volume after treatment. 
However, the immune incompetent mouse model- NOD SCID mice were used for the tumour 
model, where the impact of immune response was not taken into account. Our results 
suggest that while the small molecule interruption of E7- Rb interactions may have similar 
impact to genetically mediated blockade and enable induction of effective peripheral 
immunity, it may not be sufficient to induce a sufficient response to clear E7 infected cells. 
A combination of a small molecule inhibitor of Rb-E7 interaction, combined with more 
effective antigen presentation through immunisation, might nevertheless represent a means 
to clear E7 infected tissues.  
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3.7 Materials and Methods 
Mice  
All mice were maintained in Translational Research Institute (TRI) Biological Research 
Facility (BRF) under specific pathogen free conditions. For experimental work, female mice 
were used at 8-12wk of age. C57BL/6 and B6.SJL.Ptprca mice were obtained from Animal 
Resources Centre (Perth, Australia) and OT-1 mice were purchased from The Jackson 
Laboratories (Bar Harbor, ME, USA). K14.E7 (Herber et al., 1996) and K5mOVA (Azukizawa 
et al., 2003) mice were maintained at the TRI-BRF. Heterozygous RbΔL/ΔL transgenic and 
NKT cell deficient Jα18-/- mice (Isaac et al., 2006) were obtained from Dr Fred Dick and Mark 
Smyth (Melbourne, Australia), respectively and maintained locally at TRI-BRF. 
K14.E7xRbΔL/ΔL and Jα18-/-xE7 mice were generated by mating heterozygous K14.E7 with 
heterozygous RbΔL/ΔL and homozygous Jα18-/-, respectively. K14.E7xRbΔL/ΔL mice have a 
single allele of E7 transgene and at least one allele of mutated Rb. OT-I mice were 
purchased from The Jackson Laboratories (Bar Harbor, ME, USA). E7TCR269 mice were 
bred as previously described (Narayan et al., 2009). All procedures were approved by the 
University of Queensland Animal Ethics Committee (UQDI/367/13/NHMRC and 
UQDI/452/16).  
 
Immunisation 
Immunisations were performed by injecting 5µg QuilA (Sigma-Aldrich, St. Louis, MO, USA) 
with 50µg OVA (A5503, Sigma-Aldrich, St. Louis, MO, USA) or E7 peptide-GF001 
(RAHYNIVTF, synthesized by Auspep Pty Ltd, (Melbourne, Australia), with purity >80%) in 
20µl PBS into one ear pinnae intradermally or 200µl PBS subcutaneously.  
 
Isolation of cells from lymph node and spleen 
The isolation was done as previously described (Kuo et al., 2017). Lymph nodes were 
digested with 1μg/ μl, of collagenase D (Roche) and 0.2μg/ μl of DNase, (Roche) for 30 
minutes at 37oC prior passing through the cell strainer.  
 
FACS, antibodies and reagents 
FACS analysis were undertaken as previously described (Mattarollo et al., 2010a). Foxp3 
Fix/Perm Concentrate and Diluent kit was used for intracellular staining (eBioscience, San 
Chapter 3                                                                                   Kuo, Paula Ting-Yu, 2018 
    72 
 
Diego, USA). IFNγ was stained intracellularly. Anti-mouse monoclonal antibodies to CD45 
(30-F11), CD45.1 (A20), CD8α (53-6.7), TCRβ (H57-597), CD4 (GK1.5), EpCAM (G8.8), I-
A/I-E (MHCII) (M5/114.15.2), CD103 (M290), CD11c (HL3), CD11b (M1/70), IFNγ (XMG1.2) 
and the corresponding isotype antibodies were purchased from Biolegend (San Diego, 
USA), eBioscience (San Diego, USA), BD Bioscience (San Jose, USA) 
 
In vitro cytotoxic T cell assay 
Effector cells (E) were harvested from the spleen of E7TCR269 and OT-1 mice six days 
after GF001 and OVA immunisation, respectively. Splenocytes were cultured in standard 
RPMI and supplemented with IL-2 (1 U/mL, Peprotech, NJ, USA) overnight and CD8 T cells 
were enriched using biotinylated antibodies (Kuo et al., 2017). Target keratinocytes (T) were 
sorted using BD FACSAria Fusion Sorter and pulsed with 10 μg/mL of either GF001 or 
SIINFEKL (Sigma-Aldrich, St. Louis, MO, USA) peptide. Effector and target cells were co-
cultured at 20:1, 10:1 or 2.5:1 ratio for 5 hours and cell-mediated cytotoxicity assay was 
performed using CytoTox 96® Non-Radioactive Cytotoxicity Assay kit (Promega, Madison, 
WI, USA) following manufacturer's instruction. Percentage of cytotoxicity was calculated as 
follow (each value calculated has been subtracted with medium background):  
% 𝑜𝑓 𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 =
(𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝐾𝐶 + 𝐸7𝑇𝐶𝑅269 𝑇 𝑐𝑒𝑙𝑙𝑠 𝑎𝑡 𝑟𝑎𝑡𝑖𝑜 𝑥)−(𝑚𝑒𝑎𝑛 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝐾𝐶 𝑤𝑖𝑡ℎ 𝑛𝑜 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 + 𝑂𝑇−1 𝑇𝑐𝑒𝑙𝑙𝑠 𝑎𝑡 𝑟𝑎𝑡𝑖𝑜 𝑥)
(𝐾𝐶 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑟𝑒𝑙𝑒𝑎𝑠𝑒)−(𝑚𝑒𝑎𝑛 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝐾𝐶 𝑤𝑖𝑡ℎ 𝑛𝑜 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 + 𝑂𝑇−1 𝑇𝑐𝑒𝑙𝑙𝑠 𝑎𝑡 𝑟𝑎𝑡𝑖𝑜 𝑥)
 𝑥 100%  
 
Skin grafting  
Skin grafting was performed as previously described (Chakraborty et al., 2018). Briefly, skin 
graft recipients were shaved on the flank and shaved skin was cut out in the size that 
matches the donor skin. Ears from the donor mice were split into dorsal and ventral part and 
grafted onto recipient mice. Bactigras (Smith & Nephew, Australia) was placed, following by 
bandaging. The bandage was taken off seven days after the procedure. Day 21 post-grafting 
was set as baseline for comparison as the skin grafts are well-healed and no local 
inflammations were observed.  
  
Statistical analysis 
Prism 7 (GraphPad Software, La Jolla, CA) software was used for statistical analysis and to 
prepare the plots. Unless otherwise stated, all analyses were done using one-way ANOVA, 
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with Bonferroni’s multiple comparison tests. Two-way ANOVA with Bonferroni’s post-test 
analysis was used in Figure 3.3 and Figure 3.4. All plots show mean value with SEM. Paired-
student t-test was used in Figure 3.3b. Result significance was shown, where *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001. 
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Figure 3.1. K14.E7xRb ΔL/ΔL and non-transgenic mice respond equally to intradermal 
immunisation 
OVA specific CD8 T cell responses in the draining LN following intradermal immunisation 
were assessed as IFNγ production following in vitro re-stimulation. (a) Representative FACS 
plots pre-gated on TCRβ+ CD8 T cells showing IFNγ production with (+) or without (-) 
SIINFEKL re-stimulation. (b) Quantitative result showing mean+/-SEM with n>3 for each 
mouse type. Analyses were done using one-way ANOVA, with Bonferroni’s multiple 
comparison tests. Result significance was shown, where *p<0.05, ***p<0.001 and 
****p<0.0001.  
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Figure 3.2. K14.E7xRbΔL/ΔL skin grafts are not rejected from immunocompetent 
syngeneic recipients  
(a) Grafts of donor ear skin, as shown, onto C57BL/6 recipients at 21 and 42-days post 
grafting. (b) Area remaining of graft at the indicated time points. (c) C57BL/6 and E7TCR269 
recipients were immunised with GF001 (50 µg) and QuilA (5µg) subcutaneously seven days 
before grafting. (d) Representative photos of graft-bearing recipients on day21 and day63. 
K14.E7 skin (left) and K14.E7xRbΔL/ΔL skin (right). (e) Area remaining of graft at the indicated 
time points, compared to the graft on day 21. DPG, day post grafting. Analyses were done 
using one-way ANOVA, with Bonferroni’s multiple comparison tests. Error bars showing 
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mean+/-SEM with n3. Result significance was shown, where *p<0.05, **p<0.01, ***p<0.001 
and ****p<0.0001. 
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Figure 3.3. The presence of K14.E7xRbΔL/ΔL and K14.E7 DCs from grafted skin in the 
draining lymph node  
Skin-derived DC in graft draining and control lymph node of CD45.1 recipients receiving 
K5mOVA, C57BL/6, K14.E7, K14.E7xRbΔL/ΔL or RbΔL/ΔL (CD45.2) skin grafts. a) 
experimental outline. Draining lymph nodes (axillary and iguanual) were harvested 11 days 
after grafting from either grafted side or non-grafted side of one graft recipient. b) total 
numbers of graft-derived cells (CD45.1-), pre-gated on live CD11c+ cells, in lymph nodes of 
grafted and non-grafted side. Paired student t-test applied. c) representative plots showing 
graft-derived migratory DC numbers under live CD45.1- gate. d) quantitative result of c). e) 
gating strategy of resident DC (ResDC), migratory DC (migDC) and DC subtypes. 
Representative plots from one recipient-derived live cell gate were shown. f) numbers of 
graft derived MigDC subtypes (CD103+, CD11b+ and LC) from lymph nodes of mice 
receiving indicated skin grafts. g) MFI (top panel) and percentage (bottom panel) of CD80 
and CD86 positive cells of various DC subtypes in grafted-drianing lymph nodes receiving 
either K14.E7 (closed circle) or K14.E7xRbΔL/ΔL (opened circle) skin graft. Statistics were 
done with one-way ANOVA test with Bonferroni post-test. Panel B was done by matched 
two-way ANOVA test. All plots show mean value with SEM, n>4. Result significance was 
shown, where *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.  
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Figure 3.4. Keratinocytes from K14.E7xRb ΔL/ΔL skin present endogenous antigen and 
are susceptible to CTL-mediated lysis 
Keratinocytes isolated from the epidermis of C57BL/6, K14.E7, K14.E7xRbΔL/ΔL, and RbΔL/ΔL 
mice were pulsed with a) GF001 peptide or b) without peptide and co-cultured with E7-
specific effector T cells (E7TCR269) at the shown effector/target (E/T) ratios. Keratinocyte 
death was assessed as LDH release above background from no-peptide pulsed KC exposed 
to activated OT-1 T cells (see Methods section). Two independent experiments were done. 
Data analysed using two-way ANOVA and applied with Bonferroni post-test. Error bars 
showing mean+/- SEM with three biological replicates in each experimental group. Result 
significance was shown, where ****p<0.0001.  
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Supplementary Figures 
 
Figure S3.1 
a) Naïve lymph node from C57BL/6, B6.SJL.Ptprca and 1:1 mixture stained with CD45.1 
antibody to establish gating. Plots were pregated on live CD11c+ cells. b) Skin-derived DC 
in graft draining and control lymph node of CD45.1 recipients receiving K5mOVA, C57BL/6, 
K14.E7, K14.E7xRbΔL/ΔL or RbΔL/ΔL (CD45.2) skin grafts. Representative plots of graft-
derived cells (CD45.1-), pre-gated on live CD11c+ cells. (c) Quantitative result showing mean 
value with SEM of graft-derived cells of b). Analyses were done using one-way ANOVA, with 
Bonferroni’s multiple comparison tests. Result significance was shown, where ***p<0.001 
and ****p<0.0001. 
Chapter 3                                                                                   Kuo, Paula Ting-Yu, 2018 
    80 
 
 
Figure S3.2 
Percentage (a) and numbers (b) of recipient-derived CD11c+ cells under live CD45.1+ gate. 
Closed and open circle showing draining lymph nodes analysed from the grafted and non-
grafted site, respectively. 
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Figure S3.3 
Target spontaneous and maximum LDH release at the same target cell number in Figure 
3.4 Bar graph showing minimum and maximum absorbance at 490nm of three biological 
replicates.  
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Figure S3.4 
Control groups of antigen specific keratinocyte in vitro killing. Keratinocytes isolated from 
the epidermis of C57BL/6, K14.E7, K14.E7xRbΔL/ΔL, and RbΔL/ΔL mice were pulsed with 
GF001, SIINFEKL peptide or no peptide (-) and co-cultured with E7-specific effector T cells 
(E7TCR269) or SIINFEKL-specific effector T cells (OT-1) at the shown effector/target (E/T) 
ratios. Cytotoxicity is calculated with respect to keratinocyte death, which is assessed by 
LDH release using the following equation.  
% 𝑜𝑓 𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 =
(𝑚𝑒𝑎𝑛 𝑟𝑒𝑎𝑑) − (𝑒𝑓𝑓𝑒𝑐𝑡𝑜𝑟 𝑠𝑝𝑜𝑛𝑡𝑎𝑒𝑛𝑜𝑢𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒) − (𝐾𝐶 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒)
(𝐾𝐶 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑟𝑒𝑙𝑒𝑎𝑠𝑒) − (𝐾𝐶 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒)
 𝑥 100% 
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Discussions and Conclusion 
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4.1 Project summary 
This project focuses on distinguishing the immunological phenotype and response in 
HPV16E7-expressing skin induced by E7-Rb interaction associated skin hyperplasia from 
E7 expression. Utilising both K14.E7 and K14.E7xRbΔL/ΔL transgenic mice, I conclude that 
the hyperplastic skin environment induced by E7-Rb interaction, serves as an important 
factor that contributes to the suppressive local immunity in addition to the expression of viral 
oncoprotein E7.  
 
In chapter 2, CXCR3+ T cells are identified as a population that can facilitate E7-expressing 
skin graft rejection in the context of K14.E7xRag-/- skin graft. Chemokine ligands CXCL9 and 
CXCL10 are predominantly expressed by CD45- keratinocytes in the hyperplastic epithelium 
that direct the recruitment of CXCR3+ T cells. Although, how this population interacts with 
other immunocytes that are mostly immunosuppressive in the context of K14.E7 skin still 
need to be explored, this is the first time an effector population has been identified to be 
involved in the process of skin graft rejection.  
 
In chapter 3, I found that in the absence of E7-Rb interaction, the peripheral immune 
response is restored to a comparable level to non-transgenic wild-type. Moreover, this 
disruption allows endogenous antigen from the keratinocytes to be presented and induces 
CTL-mediated lysis in vitro. I assessed the ability of keratinocytes in presenting endogenous 
antigen by co-culturing keratinocytes, immediately after FACS sorting, with activated 
antigen-specific effector T cells. Although there are possibilities that proliferative cells (when 
E7-Rb interacts) are more insensitive/ sensitive to CTL-mediated lysis, the proliferation rate 
was not included as a factor of variables in this experiment. As keratinocytes from different 
transgenic animals were isolated the same way and co-cultured with T cells for five hours, 
which is shorter than average cell proliferation cycle, the results are conclusive. Despite that  
the keratinocytes from K14.E7xRbΔL/ΔL skin can induce CTL-mediated lysis, disruption of 
E7-Rb interaction is unable to induce graft rejection. One of the possibilities that associates 
with skin transplant tolerance is that the lymph nodes draining K14.E7xRbΔL/ΔL skin graft do 
not show increased K14.E7xRbΔL/ΔL skin-derived DCs when compare to K14.E7 or K5mOVA 
skin. This may further impact on the efficiency of T cell priming in the lymph node. This part 
of the project suggests that interference of E7-Rb interaction can partially restore effective 
immune responses, but a combination triggering proper skin-derived APC function in the 
draining lymph node may be required if this was to be implemented clinically. 
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Figure 4.1 shows a graphical summary comparing the differences between K14.E7 and 
K14.E7xRbΔL/ΔL skin phenotype.  
 
 
 
 
Figure 4.1 Comparison between K14.E7 skin and K14.E7xRbΔL/ΔL skin.  
The HPV16E7 protein interacts with cellular Rb and results in epithelial hyperplasia. i) In the 
hyperplastic K14.E7 skin, increased numbers of immunocytes including CD4, CD8 T cells, 
CD11b+ non-DC, CD11b+ DC and LC are found. ii) CD4 and CD8 T cells in the K14.E7 skin 
express higher level of co-inhibitory molecules, such as PD-1 and CTLA4. iii) Keratinocytes 
derived from the K14.E7xRbΔL/ΔL skin are able to present endogenous antigens to antigen-
specific effector T cells in vitro and induce cell-mediated lysis. iv) This part shows the non-
transgenic recipient draining lymph node when grafted with K14.E7xRbΔL/ΔL skin. Although 
the composition of DC subtypes in the K14.E7xRbΔL/ΔL skin remained similar to non-
transgenic skin, there was less CD11b+ skin-derived DC in the draining lymph nodes when 
compared with immunogenic skin controls. This may result in insufficient T cell priming by 
the skin-derived DC and further restricts skin graft rejection.   
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4.2 Hyperplastic environment as a main force to influence the immune responses and 
phenotype of infiltrated lymphocytes 
Persisting high-risk HPV infection in the cervix results in cervical intraepithelial neoplasia 
(CIN) and ultimately leads to cervical cancer. While spontaneous regression is observed at 
the early stages of CIN, the virus changes the microenvironment of the infected area during 
the course of persistent infection and evades immune surveillance through several 
mechanisms. The mechanisms include, but not restricted to, i) the preferred codon usage 
that are rarely used in mammalian cells and thus limited capsid proteins generation, which 
immune system can recognise (Zhou et al., 1999); ii) Failed maturation of HPV E7-loaded 
DC and therefore does not transmit immunogenic signal to T cells in the draining lymph node 
(Hemmi et al., 2001); iii) Regulatory T cells are generated by immature dendritic cells 
(Dhodapkar et al., 2001; Roncarolo et al., 2001) .  
In the high-risk HPV genome, E6 and E7 proteins are the oncogenes that drive 
tumour development through the interaction with p53 and Rb, respectively. E6 and E7 
impede effective immune responses mostly by changing the local environment as a 
consequence of uncontrolled cell growth. It has been widely characterized that the 
phenotype and function of tumour/hyperplasia infiltrating lymphocytes are shaped by the 
microenvironment, and the microenvironment in turn, changes the composition, as well as 
functions of tissue infiltrating lymphocytes. These changes of microenvironment induce i) a 
unique cytokine and chemokine secretion profile that alters the composition and function of 
immunocytes within the microenvironment and ii) expression of immune checkpoint 
molecules on tumour cells that attenuate effector function on lymphocytes. This project 
examines in details on the consequence of hyperproliferative epithelium, resulting from E7-
Rb interaction, the immune environment including lymphocyte recruitment, phenotypic 
changes of skin infiltrating/resident lymphocytes and antigen presentation of the 
keratinocytes.  
   
Keratinocytes in the epidermis change the cytokine and chemokine secretion profile 
in response to injuries, infections, as well as the proliferation and differentiation of 
keratinocytes (Bourke et al., 2015; Mckay and Leigh, 1991; Tuzun et al., 2007). These 
events that involve tissue structure alterationsoften lead to the overexpression of stress 
keratins, a phenotype which was also observed in the epidermis of K14.E7 (Zhussupbekova 
et al., 2016). Pro-inflammatory cytokines including IL-1, 6, 7, 10, 15, tumour necrosis factor 
α (TNFα), IFNα, β and γ are also produced (Blauvelt et al., 1996; Fujisawa et al., 1997; 
Grewe et al., 1995; Heufler et al., 1993; Howie et al., 1996; Kock et al., 1990; Kupper and 
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Groves, 1995; Oxholm et al., 1991). These cytokines and chemokines together recruit and 
activate immunocytes, therefore, change the local immune response. In addition, 
chemokines are also produced to attract leukocytes possessing cognate chemokine 
receptors to the site of inflammation (Nedoszytko et al., 2014). However, these changes can 
be reversed back to the level comparable to non-transgenic wild type when E7 can no longer 
interact with Rb. Thus, the cytokine and chemokine secretion in the epidermis of a persistent 
HPV infection mouse model, according to this study, is dependent on the interaction 
between E7 and Rb protein and the associated epidermal hyperplasia. 
  
Previous studies showed that a range of pro-inflammatory cytokines, such as IFNγ, 
secreted by NKT cells, (Mattarollo et al., 2010a), IL-17, secreted by CD4 and γδ T cells, 
(Gosmann et al., 2014b) and IL-18, which is induced by IFNγ secreting NKT cells (Gosmann 
et al., 2014a) play immune suppressive roles in E7-associated hyperplasia. It is very likely 
that the microenvironment imposes strong influence on the recruitment of these particular 
cell types and forms a positive loop that reinforce on the suppressive immunity. Other 
possible mechanisms contributing to the suppressive immunity are i) PD-L1 and/ or PD-L2 
expression on keratinocytes and/ or dendritic cells (Chandra et al., 2016) attenuate the 
effector T cell function; ii) IFNγ produced by the recruited immunocytes induces more 
expression of PD-L1 and PD-L2 (Garcia-Diaz et al., 2017); iii) IFNγ produced by NKT cells 
plays immunosuppressive role, as the E7-expressing transplants can only be rejected in the 
absence of IFNγ or NKT cells (Mattarollo et al., 2010a); iv) effector function of chemokine-
recruited T cells, such as CXCR3+ T cells, could be influenced and suppressed by cytokines 
secreted by other cell types within the environment ; v) CXCR3 is expressed on both effector 
and regulatory T cells, and thus despite the recruitment of CXCR3+ T cell to the hyperplastic 
epithelium, no inflammatory response or skin graft rejection was observed; and vi) antigen 
presentation in both keratinocytes and DCs could be impaired at any step of the antigen 
presenting process as a result of E7 expression (Li et al., 2006; Li et al., 2009; Park et al., 
2000).  
  
Chapter 4                                                                                   Kuo, Paula Ting-Yu, 2018 
    88 
 
4.3 Clinical relevance  
This study provides a greater insight to HPV16E7-associated epithelial hyperplasia in 
addition to the expression of E7 protein itself. More importantly, it is identified in this project 
that an effector population can be recruited to the E7-expressing hyperplastic epithelium 
and the signal for this lymphocyte recruitment is provided by the proliferative epithelium. 
CXCL9 and CXCL10 production can be induced by type I interferons locally through topical 
imiquimod application and draw in effector cells with boosted immune response in a 
melanoma clinical study (Mauldin et al., 2016). Imiquimod has been widely used to treat 
genital warts (Skinner, 2003) and was on a phase II trial in combination with protein based 
HPV therapeutic vaccine for grade 2 and 3 vulval intraepithelial neoplasia (VIN) (Daayana 
et al., 2010). The trial result shows significant CD4+ and CD8+ T cells infiltration and antigen 
specific proliferation in responders. As shown in Figure 2.6d, CXCR3+ CD4+ T cells are 
preferentially recruited to the K14.E7 skin graft at the experiment endpoint. It is likely that 
this population contributes highly to skin graft tolerance. Depleting CD4 T cells could then, 
in some degree, induce clearance of skin graft. Given the observations and findings in this 
project, CXCR3 signal agonists or topical imiquimod to recruit substantial amount of effector 
T cells could be implemented in conjunction with E7-targeting therapeutic vaccines for late 
stage CIN treatment.  
 
In chapter 3, we showed that disruption of E7-Rb interaction was unable to induce 
skin graft rejection, which is a critical measurement for lesion clearance. Possible 
explanations to the tolerance are i) low immunogenicity of E7 protein and ii) low level of 
antigen specific effector cell recruitment or retention in the localised area. Michal Šmahel et 
al., showed that vaccination with E7 DNA containing point mutations that disrupts the Rb-
binding site can induce protection against TC-1 tumour only when it is fused with E. coli β‐
glucuronidase (GUS), suggesting low immunogenicity of E7 (Smahel et al., 2004). 
Furthermore, in the E7-expressing normoplastic skin, low level of vascularisation as well as 
cytokine and chemokine production were observed, which are important for recruiting and 
retaining cytotoxic T cells. On the other hand, as abrogation of E7-Rb interaction significantly 
improved immune responses against vaccination and the local environment exhibited similar 
molecular and phenotypic profile to normal tissue, it is still of great potential that this could 
be implemented as one of the therapeutic strategies for persistent HPV infection. In fact, a 
small molecule antagonising Rb inactivation by HPVE7 protein has been identified (Fera et 
al., 2012). This small molecule inhibits Rb and E7 interaction by competing the Rb binding 
site with E7 and is able to selectively induce effective E7+ cell death in vitro. However, the 
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anti-tumour effect of this molecule was only tested in TC-1 tumour bearing NOD SCID 
model, which lacks competent immune system. Taken together, E7-Rb interaction and the 
associated hyperplasia can be a potential therapeutic target but may require further 
combinatorial treatment to achieve promising outcome.  
  
Current therapeutic strategies for late stage CIN or HPV-induced cervical cancer 
focuses on targeting the E7 antigen along with inducing more tissue-homing cytotoxic T 
cells. Some of the main drawbacks from current therapeutic vaccines are the concurrent 
recruitment of regulatory or suppressive lymphocytes (Welters et al., 2008) and also the lack 
of significant lesion regression when compared to spontaneous clearance (Einstein et al., 
2007). This implies that simply targeting E7 antigen may not be enough to generate sufficient 
immunity to eradicate persistent infection. One promising therapy under phase 3 clinical trial 
is VGX-3100, a DNA vaccine targeting E6 and E7 of HPV16 and HPV18developed by Inovio 
Pharmaceuticals, Inc (Morrow et al., 2016; Trimble et al., 2015). In phase 2b trial 
(NCT01304524), 40% of vaccinated women showed lesion regression, whereas only 14.3% 
regression was observed in the placebo treated group (Morrow et al., 2018). Although the 
vaccine is effective in terms of successful lesion regression and viral clearance, 60% of the 
patients were not responsive to the vaccine. This suggests that the suppressive immunity 
may still plays a significant role controlling the outcome of therapeutic effectiveness. 
Interestingly, a follow up study of this clinical trial showed a number of findings and prediction 
of clinical outcomes that coincide with the findings in the K14.E7 mouse model. In the VGX-
3100 trial study, infiltration of CD8+ cells, FoxP3+ cells, the CD8/Foxp3 ratio, or PD-L1 
expression in cervical epithelial tissue prior to treatment do not predict the clinical response. 
After final treatment with VGX-3100 but before the trial end point, increased number of T 
cell co-stimulatory marker 4-1BB+ (CD137+) CD8 T cells expressing GrzA, GrzB and Prf 
specific for the infected HPV type from the peripheral blood can be good predictive markers 
for responsive outcome. In relation to this, the K14.E7 skin has significant CD137+CD8+ T 
cells infiltration (Choyce et al., 2013) (and data not shown) and PD-L1 expression (Chandra 
et al., 2016). Moreover, depletion of FoxP3 expressing cells did not enable graft rejection, 
indicating that these cells are not critical populations contributing to skin graft tolerance 
(Mattarollo et al., 2011). These results further strengthen and support this transgenic mouse 
as a suitable model to study the suppressive immunity in persistent HPV infection and to 
improve our understanding to the therapeutic vaccine non-responders.  
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4.4 Concluding remark and future prospect  
This project reported that the local immune environment and responses in a persistent 
HPV16 infected model are mostly, but not all, the result of the HPV16E7-Rb interaction-
induced epithelial hyperplasia. This study provides a potential strategy for treatment of HPV 
related CIN. To resolve persistent HPV infection, localised effector T cells infiltration and 
antigen specific resident memory T cells establishment could be promising for future studies 
on therapeutic vaccine development.  
 
The following questions could be addressed in prospective studies: 
 
1. What are the immunocytes and/or secretory factors that positively contribute to 
HPV16E7-expressing skin graft rejection? 
The Frazer lab together has identified immunocytes and secretory factors that contribute to 
K14.E7 skin graft rejection (see Chapter 1 introduction). It was found that adoptive transfer 
of E7-specific CD8 T cells plus E7 immunisation are necessary to induce IFNγ secretion by 
antigen-specific CD8+ T cells and K14.E7 skin graft rejection (Matsumoto et al., 2004). In 
contrast to adoptive transfer, one positive regulator identified in this project that, without 
adoptive transfer or immunisation, facilitates HPV16E7-expressing skin graft clearance is 
the CXCR3+ T cell subset. In chapter 2, inhibiting the infiltration of this T cell subset was 
shown to alter the fate of hyperplastic E7-expressing skin, when no other T or B cells are 
present (K14.E7xRagKO), turning the rejection to tolerance. However, when sorted CXCR3+ 
T cells were transferred to immunocompetent recipients grafted with K14.E7 skin (shown in 
additional data, chapter 2), both control and K14.E7 skin grafts are tolerated. This indicates 
that CXCR3+ T cell alone is not sufficient, or not the dominant population, to induce K14.E7 
skin graft clearance. It would be clinically important to identify which immune population 
and/or secretory factors alone or in cooperation with CXCR3+ T cell that can actively reject 
K14.E7 skin grafts.  
 
2. Evaluate the clinical value of combining CXCR3+ T cell transfer and small molecule 
disruption of the E7-Rb interaction in treating late stage CIN.  
In chapter 2, CXCR3+ T cells are identified as an effector population that positively contribute 
to E7-expressing skin graft clearance in the absence of other lymphocytes. In chapter 3, 
although DC from the K14.E7xRbΔL/ΔL skin has limited abundance in draining lymph node, 
the in vitro result showed that keratinocytes with disrupted E7-Rb interaction can be lysed 
in a CTL-mediated fashion when sufficient effector T cells are supplied. Providing sufficient 
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effector lymphocytes to the localised area combining with E7-Rb interaction inhibitor could 
then become a possible therapeutic method to enable HPV16E7-expressing lesion 
clearance.
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Chapter 5 
 
 
 
 
 
Appendix- 
Optimisation Experiments and Extended Methods 
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5.1 Preface 
This project aims to differentiate the immune responses induced by the expression of 
HPV16E7 from the associated hyperproliferative environment. The main approach is 
utilising the K14.E7 and K14.E7xRbΔL/ΔL mice for transcriptomic and immunological analysis. 
To further investigate the impact of the HPV16E7-associated epidermal hyperplasia, some 
functional assays were designed. This chapter includes three key optimisation experiments, 
which were then further served as standard procedures in the main experiments mentioned 
in chapter 2. Also, this chapter includes one experiment, which resulted in a change of 
experimental approach due to technical difficulties. In addition to the experimental 
optimisation, this chapter also includes a section to explain the exclusions and limitations 
regarding the transgenic mouse model used.  
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5.2 Enrichment of T cells and induction of CXCR3 expression in vitro 
Corresponding to Figure 2.5 in chapter 2- in vitro trans-well migration 
The aim of the trans-well migration is to assess whether supernatants from different skin 
explant culture attract different numbers of CXCR3+ T cells as a result of the chemokines 
contained in the supernatants. To test this, equal amount of sorted CXCR3+ cells were 
seeded at the start of the experiment. Although, CXCR3+ T cells can be sorted directly from 
the spleen of a naïve non-transgenic animal, the total number of cells that can be obtained 
is not enough for a comprehensive trans-well migration experiment. Therefore, an 
alternative method was developed to obtain optimal number and consistent CXCR3-
expressing T cells. This section contains two parts- enrichment of T cells, and the induction 
of CXCR3 expression on the enriched T cells in vitro. 
 
Enrichment of T cells from naïve non-transgenic spleen using a novel antibody cocktail 
The concept of this enrichment assay is negative selection. Single cell suspension from the 
spleen was obtained with standard procedure. For one reaction, 1 x 108 cells was incubated 
with an 1 mL cocktail containing 5% rat serum, biotin-conjugated antibodies- CD19 (clone 
6D5, Biolegend, San Diego, USA), CD11b (clone M1/70, Biolegend, San Diego, USA) and 
CD11c (clone N418, Biolegend, San Diego, USA) in 1:200 dilution in FACS buffer for 15 
minutes at room temperature. Strepavidin beads (EasySep™ Streptavidin RapidSpheres™ 
50001, STEMCELL technologies, Canada) were mixed thoroughly and 75 μl was added into 
each 1ml reaction and let sit at room temperature for 2 minutes. FACS buffer was added to 
top up the volume to 2.5 ml/reaction before placed in the EasySep™ Magnet (STEMCELL 
technologies, Canada). T cells were extracted from the unbound portion and were counted 
for further use.  
  
 The enrichment increased the T cell population to 93% from 54% per spleen (about 
72 % efficiency) (Figure 5.1). Also, non-T cell population decreased, from 39% to 7% (about 
82% reduction efficiency). This showed that the assay has successfully enriched a pool of 
T cells from a naïve non-transgenic spleen.  
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Figure 5.1 T cell percentage before and after enrichment with homemade antibody 
cocktail 
Splenocytes were purified as described above and analysed under live cell gate. TCRβ was 
used as T cell marker. Left, before enrichment; Right, after enrichment.  
 
Induction of CXCR3 expression on enriched T cells 
The main purpose of inducing CXCR3 expression is to test how many cells are attracted by 
various skin explant supernatant. Consistent CXCR3 expression on T cells is required to 
assess the variability of ligands in different supernatants. As CXCR3 is a chemokine 
receptor that is expressed on activated T cells, in vitro activation of enriched T cells with 
various methods were employed. As described before, CXCR3 expression does not 
coincide with the expression level of known activation markers (CD69 and CD44) (Nakajima 
et al., 2002). Therefore, different time points were analysed to find out the optimal time point 
where a larger percentage of cells expressing CXCR3 were identified. A table below 
summarises the conditions tested.  
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Table 5.1 Conditions tested for optimal CXCR3 expression on enriched T cells 
(In each 48-well, 2 x 105 cells were seeded; all condition contains IL-2) 
PMA 25 ng/mL; Ionomycin (Ion) 1 µg/mL; anti-CD3 2 µg/mL; anti-CD28 2 µg/mL; IL-2 5 
ng/mL 
 
The result showed that after 2-days stimulation (Figure 5.2-B, E and H), a larger proportion 
of CXCR3+ cells can be detected when compared with 1-day (Figure 5.2-A, D and G) and 
7-days (Figure 5.2-C, F and I) stimulation. Surprisingly, non-stimulated group (B) has higher 
percentage of CXCR3+ cells, when compared with other stimulations, but with limited 
activation marker expression. While CXCR3 was expressed on cells receiving no 
stimulation, the viability under this condition was lower than those receiving activation. 
Therefore, this condition was not considered optimal. Stimulation with PMA/Ion (group E) 
and anti-CD3/28 antibody (group H) generate similar amount of total CXCR3+ cells on day 
5. As anti-CD3/28 treatment resulted in more CXCR3+CD69+ cells, indicating more 
activation, this condition was chosen as the optimal condition among those tested.  
Group  Condition Time point Activation markers used 
A No treatment (-) 1 Day CD69 
B No treatment (-) 2 Days CD69 
C No treatment (-) 7 Days CD44 
D PMA/ Ion 1 Day CD69 
E PMA/ Ion 2 Days CD69 
F PMA/ Ion 7 Days CD44 
G anti-CD3/28 1 Day CD69 
H anti-CD3/28 2 Days CD69 
I anti-CD3/28 7 Days CD44 
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Figure 5.2 Induction CXCR3 expression with various in vitro stimulation.  
Enriched T cells were stimulated with PMA/Ion (D, E and F) or anti-CD3/28 (G, H and I) or 
without stimulation (A, B and C). The panels in this figure are outlined in Table 5.1. All 
analysis were done on live cells. Isotype controls were used for gating.  
 
The strategy employed above was repeated twice and the results were consistent. 
However, less than 5% recovery from live cells was not ideal nor efficient. According to 
Nakajima et al. (Nakajima et al., 2002), CXCR3 expression can be induced on T cells from 
lymph node with immobilised anti-CD3/28 stimulation following with one day of stimulant 
withdraw. To test this protocol, 24-well plate was coated with anti-CD3/28 (both at 5 µg/mL) 
in Tris buffer (pH=9.4) at 4oC overnight. Splenic T cells were enriched using homemade 
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antibody cocktail. The coated plate was washed with PBS and T cells were seeded at 2.5 x 
106 cells/ well. The plate was centrifuged at 350g for 5 minutes to allow T cells contacting 
the coated surface. The cells were cultured for 48 or 72 hours with various conditions. The 
conditions tested are as below:  
 
Table 5.2 Conditions tested for optimal CXCR3 expression using immobilised antibodies 
Group 0 to 48 hours 48 to 72 hours 
A No stimulant (-) N/A 
B anti-CD3/28 N/A 
C No stimulant (-) No stimulant (-) 
D anti-CD3/28 anti-CD3/28 
E anti-CD3/28 No stimulant (-) 
  
In group B, 48 hours of immobilised antibody stimulation generated 2% CXCR3+ T 
cells of live cells, which was less than 72 hours of continuous stimulation (4.1% of live cells 
in group D). By plating cells to fresh complete RPMI after 48-hour culture for another 24-
hour (group E), the percentage increased up to 29%, which was more than 6-fold higher 
compared to the previous method and to group D in this same experiment. Therefore, this 
condition was chosen to induce surface CXCR3 expression on enriched T cells as standard 
procedure for further experiments.  
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Figure 5.3 Induction CXCR3 expression with immobilised antibody in vitro stimulation 
Enriched T cells were used for stimulation. The panels in this figure are outlined in Table 5.2 
and all analysed on live cells. Isotype controls were used for gating.  
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5.3 Establishing positive controls and neutralising antibody dose for in vitro 
chemotaxis  
The following experiment outlines how the concentration of recombinant CXCL9 (Murine 
MIG, 250-18, Lonza, Basel, Switzerland) and CXCL10 (Murine IP-10, 250-16, Lonza, Basel, 
Switzerland) was determined as chemotaxis positive control, as well as the concentration 
required for the neutralising antibody to capture the CXCL9 and CXCL10 existed in the skin 
culture supernatant (correspond to in vitro trans-well migration assay in chapter 2).  
 
The receptor CXCR3 internalises when it engages with its ligands. Given this nature, 
the amount of recombinant ligands required to achieve receptor internalisation can be 
determined by the amount of surface CXCR3. Using the optimised protocol outlined in 
section 4.2 and 4.3, CXCR3+ T cells were sorted and incubated with ligand or ligand/ 
neutralising antibody containing medium. Conditions tested are outlined in the table below:  
 
Table 5.3 Concentration tested to establish positive controls and neutralising antibody 
dose 
Ligand Ligand concentration Ligand to nAb ratio 
CXCL9 
0 nM n/a 
10 nM n/a 
50 nM n/a 
100 nM n/a 
50 nM 1:10 
50 nM 1:25 
CXCL10 
0 nM n/a 
10 nM n/a 
50 nM n/a 
100 nM n/a 
50 nM 1:10 
50 nM 1:25 
 Neutralising antibody (nAb) to CXCL9 (AF-492-NA, R&D, MN, USA), CXCL10 (AF-466-NA, 
R&D, MN, USA) isotype antibody (Goat IgG, AB-108-C, R&D, MN, USA) were used. 
Concentration of the nAb was tested with two different ratios: 1 ng of antibody neutralises 
10 ng of ligand (1:10) or 1 ng of antibody neutralises 25 ng of ligand (1:25). 
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Sorted CXCR3+ T cells were incubated with the medium at density 3x105/ 96-well 
37oC for 60 minutes. Surface CXCR3 was then stained after culture. The surface CXCR3 
decreased as the amount of ligand increased. A sharp descend of surface CXCR3 was 
observed when cultured with 50nM CXCL9 and 10 nM CXCL10. Therefore, these two 
concentrations were used as positive controls for trans-well migration experiment. nAb 
against CXCL9 used at ratio 1:10 successfully blocked the ligand and receptor binding and 
restored the surface CXCR3 to a level comparable to 0 nM. Although the nAb against 
CXCL10 did not fully restore surface CXCR3 at 1:10 ratio, this was considered effective, 
mainly because isotype control at the same ratio showed the same level of internalisation to 
that of 50nM ligand. Thus, ratio 1:10 was chosen as neutralizing condition.  
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Figure 5.4 Percentage of surface CXCR3 after culture with ligand or ligand/ nAb 
containing medium.  
Sorted CXCR3+ T cells were incubated with either CXCL9 or CXCL10 at different 
concentration with or without neutralising antibody (nAb) or isotype control antibody at 
different ratio. The mean fluorescent intensity (MFI) of 0nM was set as 100%. MFI from 
every other condition was compared to 0nM.  
 
Chapter 5                                                                                   Kuo, Paula Ting-Yu, 2018 
    103 
 
5.4 Estimation of the amount of CXCL9 and CXCL10 present in K14.E7 skin explant culture 
supernatant 
As the neutralising antibody was meant to neutralise the existing ligands contained in the 
K14.E7 skin supernatant, it was required to determine how much ligand was present in the 
supernatant. Combining the result of this section with section 5.3, which tells the ratio of 
ligands to nAb, the amount of nAb to be used can thus be finalised. Although the amount of 
CXCL9 and CXCL10 can be determined using ELISA, which requires larger volume of 
supernatant in total from more animals, due to the limitation on the numbers of animals 
granted in the ethics, an alternative method was utilised. 
 
The same culture experiment, as described in section 5.3, was used. Additional 
conditions where K14.E7 skin explant culture supernatant was diluted with complete RPMI 
as culture medium were added. The supernatant used here was a pooled sample from three 
supernatant. The rest of the un-pooled supernatant aliquots were kept for further 
experimental use to minimise the amount of experimental animals required. Without dilution, 
K14.E7 skin supernatant induced around 25% surface CXCR3 internalisation. As the 
supernatant diluted, the amount of surface CXCR3 increased, indicating less ligands in the 
medium. To conclude, there is approximately 100nM of CXCL9 and 50nM of CXCL10 in the 
K14.E7 skin supernatant.  
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Figure 5.5 Percentage of surface CXCR3 after culture with K14.E7 skin explant culture 
supernatant at various dilution.  
Sorted CXCR3+ T cells were incubated with either CXCL9 or CXCL10 at different 
concentration or with pooled K14.E7 skin culture supernatant. K14.E7 skin supernatant was 
Chapter 5                                                                                   Kuo, Paula Ting-Yu, 2018 
    104 
 
diluted with complete RPMI in 1 to 0 (pink), 1 to 1 (blue) and 1 to 2 (purple) ratio. MFI from 
every condition was compared to 0nM, which was set as 100%.  
5.5 In vivo transfer of sorted CXCR3+ T cells and track the migration of transferred cells 
In chapter 2, we observed increased expression of CXCL9 and CXCL10 in the skin of 
K14.E7. We therefore wonder what the main function of CXCR3+ T cells is once they get 
into the K14.E7 skin. The approach was to coat sorted CXCR3+ T cells (congenic 
background expressing CD45.1), generated in vitro using the procedure outlined in section 
5.2, with traceable fluorescent dye, transfer them to K14.E7 mice intravenously and track 
the transferred cells at various time points in spleen, lymph nodes and ear skin. A more 
detailed procedure is outlined below.  
 
In vitro induction of CXCR3 following method developed in section 4.2 were performed using 
splenocytes from B6.SJL.Ptprca mice and sorted into two populations- CXCR3+TCRβ+ and 
CXCR3- TCRβ+ using BD FACSAria Fusion sorter (BD Biosciences, NJ, USA). Figure 5.6 
showing representative results, which CXCR3+TCRβ+ and CXCR3- TCRβ+ can be sorted at 
percentages 5.2% and 52% of total events, respectively. CXCR3+TCRβ+ and CXCR3- 
TCRβ+ population were then coated with fluorescent dye eFluor 670 (65-0840-85, 
eBioscience, ThermoFisher, MA, USA) and CFSE (65-0850-84, eBioscience, 
ThermoFisher, MA, USA), respectively. Figure 5.7 showing representative plots immediately 
after coating. Coated cells were then mix at 1:1 ratio and 500,000 cells in total were injected 
to each recipient. Spleen, lymph nodes and ear skin were harvested on day 5, day 8 and 
day 10 for further analysis.  
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Figure 5.6 Representative CXCR3 and TCRβ sorting result.  
Pre-gated on live cells, CXCR3+TCRβ+ (P6 gate) and CXCR3- TCRβ+ (P5 gate) population 
were sorted. Post-sorting purity of both populations are >90%.  
 
Figure 5.7 Fluorescent dye coating on sorted 
CXCR3+TCRβ+ and CXCR3- TCRβ+ mixture before 
injection.  
eFluor 670 coated CXCR3+TCRβ+ and CFSE coated 
CXCR3- TCRβ+ cells were detected by APC and FITC 
channel, respectively. The two sorted populations 
were mixed after coating separately in 1:1 ratio and 
analysed by FACS prior to injection.  
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Figure 5.8 Representative plots showing analysis on transferred CXCR3+ and CXCR3- 
cells of recipient spleen, lymph node and ear skin.  
Sorted cells were coated with fluorescent dye (CXCR3+-eFluor 670; CXCR3—CFSE), mixed 
at 1:1 ratio in a total of 500,000 cells and transferred intravenously to congenic recipients 
(CD45.2). Tissues from the recipients were harvested 5, 8 and 10 days after transfer. All 
plots were pre-gated on live CD45.1 T cells.  
 
From nine donor mice, after T cell enrichment, in vitro stimulation and sorting for 
CXCR3 expression, about 2x106 of CXCR3+ T cells could be obtained. Each recipient 
received 250,000 CXCR3+ T cells and a total of eight mice can be transferred. The spleen, 
lymph node and skin of the recipient mice were collected 5, 9 and 10 days after cell transfer 
and analysed under CD45.1 T cell gate (Figure 5.8). The fluorescent coating was mostly not 
detectable at any time point experimented, suggesting that the transferred cells might have 
proliferated or the fluorescent coating is no longer detectable. Moreover, the amount of cells 
is insufficient for further analysis at any given time point in the skin of the recipient mice. The 
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reason might be that the transferred cells travel and can be recruited to any area of the skin, 
but only ear skin can be further analysed using the establish protocol. As a result, the events 
acquired are not enough to be analysed properly. Due to the technical difficulty and low cost-
effective outcome of this experiment, an alternative method was sought. Splenocytes from 
congenic donor were injected, without sorting, into recipients bearing skin grafts along with 
either vehicle or CXCR3-antagonist treatment. This allows a localised area, the skin graft, 
to be analysed and direct comparison between different skin grafts side by side, as well as 
different lymphoid organs. Moreover, the specific recruitment of CXCR3+ T cells can be 
distinguished by CXCR3-antagonist treatment, following by FACS analysis. This alternative 
approach and results are included in Figure 5 of chapter 2. 
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5.6 Exclusions and limitations  
In this section, I address some exclusions and limitations for the project due to animal 
breeding difficulties in this project. 
The Rb mutant mice used in this project are mostly heterozygotes, with only one 
allele that has the mutated E7-interaction site. The female breeders tend not to keep 
homozygotic Rb mutant pups during the weaning process, which includes less milk feeding 
and nursing, eventually these pups do no survive the weaning process. This made it difficult 
to obtain sufficient mature animals for experiments. With a few homozygotic animals 
obtained, I analysed and compared the skin histology between them and heterozygotes. At 
the molecular level, heterozygous Rb mutant provides one copy of Rb to interact with E7, 
but the thickness of the skin between homozygotes and heterozygotes remains similar. 
Phenotypically, the composition of the immunocytes in the skin showed no difference 
between homozygotic and heterozygotic Rb mutant in E7-expressing transgenic mice. This 
suggests that E7-induced hyperproliferation could be suppressed with only disrupting a 
single copy of E7-Rb interaction. In fact, it is expected that with one copy of Rb still 
functioning, without E7-induced degradation, the cell cycle should remain controlled. Figure 
5.9 and Figure 5.10 showing the analysis of immunocyte subpopulations in the epidermis 
and dermis, respectively, by FACS. In the epidermis, CD3ε+ cells, including αβ T cells and 
γδ T cells, and CD11b+ myeloid cells were analysed under live CD45+ gate, showing little 
and insignificant differences in percentage of gated. CD11c+ and MHCII+ DC was analysed 
under CD3ε- cell gate. Gated on EpCAM, LC also showed insignificant difference between 
homozygotic and heterzygotic K14.E7xRbΔL/ΔL skin. Dermal immunocyte populations 
including CD3ε+ T cells, DC, LC, macrophages, and Ly6C+ and Gr1+ monocytes were 
analysed. As there were no major phenotypic differences, homozygotic Rb mutant mice 
were not separated from heterozygotes Rb mutant mice and the two genotypes were 
combined to provide sufficient biological replicates in every experiment.  
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Figure 5.9 Representative plot of epidermal immunocyte composition in homozygotic 
and heterozygotic K14.E7xRbΔL/ΔL skin 
Composition of immunocytes in the epidermis. a and d) CD3ε+ and CD11b+ cells gated 
under live CD45+ gate. b and e) CD11c+ and MHCII+ DC gated on CD3ε- cells. c and f) LC 
gated under DC gate.  
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Figure 5.10 Representative plot of dermal immunocyte composition in homozygotic 
and heterozygotic K14.E7xRbΔL/ΔL skin 
a and f) gated under live CD45+ cell gate. b and g) CD11c+ and MHCII+ DC gated on CD3ε- 
cells. c and h) LC and dermal DC (CD11b+ EpCAM-) were analysed under DC gate in b and 
g, respectively. d and i) Macrophages were analysed under CD11b+ gate in a and f, 
respectively. e and j) F4/80- cells were further analysed based on expression of Ly6C and 
Gr1.  
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